Rivaroxaban or Aspirin for Extended Treatment of Ven

New England Journal of Medicine

376, 1211-1222

DOI: 10.1056/nejmoa1700518

Citation Report

#	Article	IF	Citations
1	Scientific Surgery June 2017 BJS. British Journal of Surgery, 2017, 104, 946-946.	3.9	1
2	Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 2491-2492.	76.6	2
3	Current Challenges and Future Prospects in Oral Anticoagulant Therapy. British Journal of Haematology, 2017, 178, 838-851.	3.2	38
4	Recanalization Rate in Patients With Proximal Vein Thrombosis Treated With the Direct Oral Anticoagulants. Thrombosis Research, 2017, 153, 97-100.	2.9	34
5	Risk of Recurrence Lower With Rivaroxaban Than Aspirin. Nature Reviews Cardiology, 2017, 14, 254-255.	62.4	1
6	Residual Vein Thrombosis and Serial D-Dimer for the Long-Term Management of Patients With Deep Venous Thrombosis. Thrombosis Research, 2017, 154, 35-41.	2.9	29
7	Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1279-1280.	76.6	4
8	A Test in Context: D-Dimer. Journal of the American College of Cardiology, 2017, 70, 2411-2420.	12.0	539
9	Arzneiverordnungs-Report 2017. , 2017, .		85
10	Optimal Long-Term Pharmacological Treatment of Patients With Venous Thromboembolism That Was Unprovoked or Associated With Weak Risk Factors. Expert Review of Hematology, 2017, 10, 921-931.	2.7	0
11	Use of Direct Oral Anticoagulants in Patients on Immunomodulatory Agents. Journal of Thrombosis and Thrombolysis, 2017, 44, 298-302.	2.2	21
12	Stopping Anticoagulation in a Woman With Unprovoked Venous Thromboembolism. Cmaj, 2017, 189, E1112-E1114.	1.8	4
13	Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. Techniques in Vascular and Interventional Radiology, 2017, 20, 141-151.	1.6	9
14	Quel traitement anticoagulant au décours d'une embolie pulmonaire. Presse Medicale, 2017, 46, 728-738.	4.8	1
15	The Paradoxical Association Between Pulmonary Embolism and COPD. European Respiratory Journal, 2017, 50, 1700959.	11.5	7
16	External Validation of the DASH Prediction Rule: A Retrospective Cohort Study. Journal of Thrombosis and Haemostasis, 2017, 15, 1963-1970.	5.0	73
17	Deciphering Conformational Changes Associated With the Maturation of Thrombin Anion Binding Exosite I. Biochemistry, 2017, 56, 6343-6354.	2.9	3
18	How I Treat Heavy Menstrual Bleeding Associated With Anticoagulants. Blood, 2017, 130, 2603-2609.	10.6	56

#	Article	IF	Citations
19	Verlängerte VTE-Prophylaxe: Rivaroxaban Deutlich Besser Als ASS. CardioVasc, 2017, 17, 18-19.	0.0	0
20	Is It Reasonable to Use a Lower DOACs Dose in Some Patients With VTE? Yes. Internal and Emergency Medicine, 2017, 12, 561-563.	4.8	2
21	Venous Thromboembolism in Portuguese Hospitals: Where We Stand and How We Can Improve. Revista Portuguesa De Cardiologia, 2017, 36, 831-832.	1.1	1
22	Venous Thromboembolism in Portuguese Hospitals: Where We Stand and How We Can Improve. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 831-832.	0.6	0
23	Secondary Prevention of Recurrent Venous Thromboembolism After Initial Oral Anticoagulation Therapy in Patients With Unprovoked Venous Thromboembolism. Cochrane Database of Systematic Reviews, 2017, 12, CD011088.	6.9	17
24	Tiefe Venenthrombose: Wie Lang Antikoagulieren?. CME (Berlin, Germany), 2017, 14, 54-54.	0.0	0
25	ACC Highlights Promising Studies. Pharmacy Today, 2017, 23, 2.	0.0	0
26	Recent Advances in the Treatment of Venous Thromboembolism in the Era of the Direct Oral Anticoagulants. F1000Research, 2017, 6, 985.	1.1	28
27	Report of the Annual Scientific Sessions of the American College of Cardiology (ACC), Washington DC. Circulation Journal, 2017, 81, 777-782.	4.0	3
28	Hybrid Strategy to Prevent Venous Thromboembolism After Joint Arthroplasty. New England Journal of Medicine, 2018, 378, 762-763.	76.6	6
29	The Year 2017 in Cardiology: Aorta and Peripheral Circulation. European Heart Journal, 2018, 39, 730-738.	14.7	9
30	Transitioning Between Anticoagulants. , 2018, .		0
31	Anticoagulation in Venous Thromboembolism. , 2018, .		0
32	Plasma Contact Factors as Therapeutic Targets. Blood Reviews, 2018, 32, 433-448.	7.6	61
33	The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease. Thrombosis and Haemostasis, 2018, 118, S2-S11.	4.6	2
34	Interference of DOACs in Different DRVVT Assays for Diagnosis of Lupus Anticoagulants. Thrombosis Research, 2018, 165, 101-106.	2.9	29
35	Introduction to the Vascular Medicine Issue of Progress in Cardiovascular Diseases. Progress in Cardiovascular Diseases, 2018, 60, 565-566.	9.7	2
36	Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?. Progress in Cardiovascular Diseases, 2018, 60, 607-612.	9.7	3

#	Article	IF	Citations
37	New Trends in Anticoagulation Therapy. Surgical Clinics of North America, 2018, 98, 219-238.	2.6	24
38	Daily 10 mg Rivaroxaban as a Therapy for Ventricular Thrombus Related to Left Ventricular Non-Compaction Cardiomyopathy: A Case Report. Medicine (United States), 2018, 97, e9670.	2.1	22
39	Verlängerte Sekundärprophylaxe nach venöser Thromboembolie. Deutsche Medizinische Wochenschrift, 2018, 143, 137-142.	0.3	6
40	A COMPASS to REACH the Right Patients With Thrombocardiology: Benefits, Risks, and Future of the New Concept. European Heart Journal, 2018, 39, 758-761.	14.7	7
41	Management of Heavy Menstrual Bleeding During Direct Oral Anticoagulant Therapy for Recurrent Venous Thromboembolism: A Case Report. Blood Coagulation and Fibrinolysis, 2018, 29, 391.	1.0	3
42	Study Protocol for the Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study. Journal of Comparative Effectiveness Research, 2018, 7, 57-66.	2.7	2
43	Anticoagulantes Orales Directos: Puesta Al Día. Medicina Clínica, 2018, 151, 198-206.	1.2	36
44	Pulmonary Embolism: Care Standards in 2018. Progress in Cardiovascular Diseases, 2018, 60, 613-621.	9.7	15
45	Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie. Herz, 2018, 43, 34-42.	1.8	3
46	The Year in Cardiology 2017: Prevention. European Heart Journal, 2018, 39, 345-353.	14.7	3
47	Anticoagulants oraux directs (AOD) : une mise au point nécessaire. JMV-Journal De Medecine Vasculaire, 2018, 43, 198-205.	1.2	2
48	Thrombose, Lungenembolie und Antikoagulation. Klinikarzt, 2018, 47, 86-94.	0.0	0
49	Cardioembolic Stroke: Everything Has Changed. Stroke and Vascular Neurology, 2018, 3, 76-83.	5.1	48
50	Pulmonary Embolism. MMW Fortschritte Der Medizin, 2018, 160, 48-56.	0.0	0
51	Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2018, 44, 261-266.	4.1	16
52	Rivaroxaban Versus Nadroparin for Preventing Deep Venous Thrombosis After Total Hip Arthroplasty Following Femoral Neck Fractures: A Retrospective Comparative Study. Journal of International Medical Research, 2018, 46, 1936-1946.	2.0	9
53	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Thrombosis and Haemostasis, 2018, 118, S23-S33.	4.6	10
54	More Efficacious, Equally Safe: A Meta-Analysis Comparing the Safety of Direct Oral Anticoagulants Versus Aspirin. Journal of Thrombosis and Thrombolysis, 2018, 46, 22-23.	2.2	3

#	Article	IF	Citations
55	Non-Vitamin K Antagonist Oral Anticoagulants for Pulmonary Embolism: Who, Where and for How Long?. Expert Review of Respiratory Medicine, 2018, 12, 387-402.	3.4	4
56	The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. European Heart Journal, 2018, 39, 1330-1393.	14.7	1,815
57	Venous Thromboembolism Therapy With Rivaroxaban in Daily-Care Patients: Results From the Dresden NOAC Registry. International Journal of Cardiology, 2018, 257, 276-282.	3.2	23
58	A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism. Cardiology and Therapy, 2018, 7, 1-13.	3.6	21
59	Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document From the European Society of Cardiology Working Groups of Aorta and Peripheral Vascular Diseases and Pulmonary Circulation and Right Ventricular Function. European Heart Journal, 2018, 39, 4208-4218.	14.7	344
60	Venous and Arterial Thromboses: Two Sides of the Same Coin?. Seminars in Thrombosis and Hemostasis, 2018, 44, 239-248.	4.1	84
61	Residual Pulmonary Embolism as a Predictor for Recurrence After a First Unprovoked Episode: Results From the REVERSE Cohort Study. Thrombosis Research, 2018, 162, 104-109.	2.9	34
62	Update on the Use of Direct Oral Anticoagulants for the Prevention and Treatment of Thromboembolism. Future Cardiology, 2018, 14, 89-99.	1.2	0
63	Calculation of HAS-BLED Score Is Useful for Early Identification of Venous Thromboembolism Patients at High Risk for Major Bleeding Events: A Prospective Outpatients Cohort Study. Seminars in Thrombosis and Hemostasis, 2018, 44, 348-352.	4.1	20
64	Clinical Outcomes of Prolonged Anticoagulation With Rivaroxaban After Unprovoked Venous Thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 58-68.	3.3	7
65	Electrical Calf Muscle Stimulation in Patients With Post-Thrombotic Syndrome and Residual Venous Obstruction After Anticoagulation Therapy. International Angiology, 2018, 37, 400-410.	1.8	9
66	Employing the European Thyroid Imaging Reporting and Data System 2017 Classification in a Malignancy Risk Stratification System for Thyroid Nodules at Can Tho Oncology Hospital From 2021 to 2023. Italian Journal of Medicine, 2018, 12, 235-244.	0.3	1
67	Model-Based Meta-Analysis to Evaluate Optimal Doses of Direct Oral Factor Xa Inhibitors in Atrial Fibrillation Patients. Blood Advances, 2018, 2, 1066-1075.	6.3	16
68	Breadth of Complications of Long-Term Oral Anticoagulant Care. Hematology, 2018, 2018, 432-438.	2.5	33
69	Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives. Hamostaseologie, 2018, 38, 75-86.	1.5	3
70	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. Annals of Vascular Diseases, 2018, 11, 265-276.	0.7	8
71	Antithrombotic Therapy With Rivaroxaban in Five Patients With Paroxysmal Nocturnal Haemoglobinuria and Thrombotic Events. Thrombosis Journal, 2018, 16, 1-4.	2.9	6
72	Venous Thromboembolism in Multiple Myeloma – Choice of Prophylaxis, Role of Direct Oral Anticoagulants and Special Considerations. British Journal of Haematology, 2018, 183, 538-556.	3.2	58

#	Article	IF	Citations
73	Doac. The Japanese Journal of Phlebology, 2018, 29, 25-31.	0.3	0
74	Anticoagulating Patients With High-Risk Acquired Thrombophilias. Blood, 2018, 132, 2219-2229.	10.6	18
75	Advances in Stroke Prevention. Journal of Translational Internal Medicine, 2018, 6, 105-114.	9.3	17
76	A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism. Clinical Therapeutics, 2018, 40, 2140-2167.	3.4	21
77	Tratamiento anticoagulante extendido de la enfermedad tromboembólica venosa con anticoagulantes orales directos. Semergen, 2018, 44, 500-503.	0.9	0
78	Residual Pulmonary Vascular Obstruction and Recurrence After Acute Pulmonary Embolism: Protocol for a Systematic Review and Meta-Analysis of Individual Participant Data. BMJ Open, 2018, 8, e023939.	2.7	4
79	Let's Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. Circulation, 2018, 138, 2591-2593.	24.6	30
80	Direct Oral Anticoagulants and Travel-Related Venous Thromboembolism. Open Medicine (Poland), 2018, 13, 575-582.	1.8	8
81	The Prevention of Venous Thromboembolism Recurrence in the Elderly: A Still Open Issue. Expert Review of Hematology, 2018, 11, 903-909.	2.7	13
82	The American College of Chest Physician Score to Assess the Risk of Bleeding During Anticoagulation in Patients With Venous Thromboembolism: Reply. Journal of Thrombosis and Haemostasis, 2018, 16, 2539-2540.	5.0	4
83	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants. Mayo Clinic Proceedings, 2018, 93, 1503-1519.	3.7	14
84	Bleeding in Patients Receiving Non-Vitamin K Oral Anticoagulants: Clinical Trial Evidence. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 361-380.	4.0	21
85	Update on Diagnosis and Anticoagulant Therapy for Venous Thromboembolism. Internal Medicine Journal, 2018, 48, 1175-1184.	1.6	10
86	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. Seminars in Thrombosis and Hemostasis, 2018, 44, 813-822.	4.1	13
87	Update on Extended Treatment for Venous Thromboembolism. Annals of Medicine, 2018, 50, 666-674.	5.0	22
88	Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA - Journal of the American Medical Association, 2018, 320, 1583-1594.	37.0	328
89	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. Side Effects of Drugs Annual, 2018, 40, 447-461.	0.0	0
90	Health-Care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest, 2018, 154, 1371-1378.	5.9	8

#	Article	IF	Citations
91	Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies. Cardiovascular Diabetology, 2018, 17, 1-17.	15.7	665
92	Who Should Get Long-Term Anticoagulant Therapy for Venous Thromboembolism and With What?. Hematology, 2018, 2018, 426-431.	2.5	9
93	Role of the Anticoagulant Monitoring Service in 2018: Beyond Warfarin. Hematology, 2018, 2018, 348-352.	2.5	27
94	Anticoagulating Patients With High-Risk Acquired Thrombophilias. Hematology, 2018, 2018, 439-449.	2.5	11
95	Risk of Recurrent Venous Thromboembolism According to Baseline Risk Factor Profiles. Blood Advances, 2018, 2, 788-796.	6.3	93
96	Who Should Get Long-Term Anticoagulant Therapy for Venous Thromboembolism and With What?. Blood Advances, 2018, 2, 3081-3087.	6.3	23
97	Direct Factor Xa Inhibitor in the Prevention of Thromboembolism. Health Problems of Civilization, 2019, 12, 247-254.	0.3	1
98	How I Diagnose and Treat Venous Thromboembolism in Sickle Cell Disease. Blood, 2018, 132, 1761-1769.	10.6	39
99	Pulmonary Embolism. Nature Reviews Disease Primers, 2018, 4, 1-18.	81.2	331
100	Reduced-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 1288-1295.	5.0	81
101	The Use of Direct Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism in Cancer Patients. Expert Review of Hematology, 2018, 11, 487-494.	2.7	1
102	Pleiotropic Effects of the Hemostatic System. Journal of Thrombosis and Haemostasis, 2018, 16, 1464-1473.	5.0	15
103	The Secondary Prevention of Venous Thromboembolism: Towards an Individual Therapeutic Strategy. Vascular, 2018, 26, 670-682.	1.1	3
104	Initiale Antikoagulation und verlängerte Sekundärprophylaxe nach venöser Thromboembolie. Gefasschirurgie, 2018, 23, 248-253.	0.4	1
105	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. Advances in Therapy, 2018, 35, 899-927.	5.0	2
106	Influence of Age on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Rivaroxaban. Current Medical Research and Opinion, 2018, 34, 2053-2061.	2.9	10
107	Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient With Hereditary Protein S Deficiency. Case Reports in Hematology, 2018, 2018, 5217301.	0.8	8
108	The Management of Venous Thromboembolic Disease: New Trends in Anticoagulant Therapy. Advances in Surgery, 2018, 52, 43-56.	2.1	1

#	Article	IF	Citations
109	Direct Oral Anticoagulants: An Update. Medicina Clínica (English Edition), 2018, 151, 198-206.	0.2	16
110	Antithrombotic Therapy for Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention With Stent: The Case of Venous Thromboembolism. International Journal of Cardiology, 2018, 269, 75-79.	3.2	6
111	Empfehlungen zur Anwendung der indirekten und direkten Antikoagulanzien zur langfristigen Sekundärprophylaxe nach venösen Thromboembolien. Zentralblatt Fur Chirurgie, 2018, 143, 526-532.	0.4	2
112	Hypercoagulable States in Arterial and Venous Thrombosis: When, How, and Who to Test?. Vascular Medicine, 2018, 23, 388-399.	2.3	35
113	Antithrombotic Potential of Esculin 7, 3', 4', 5', 6'-O-Pentasulfate (EPS) for Its Role in Thrombus Reduction Using Rat Thrombosis Model. International Journal of Biological Macromolecules, 2018, 119, 360-368.	8.4	24
114	Bullous Hemorrhagic Dermatosis Is an Under-Recognized Side Effect of Full Dose Low-Molecular Weight Heparin: A Case Report and Review of the Literature. Experimental Hematology and Oncology, 2018, 7, 1-7.	15.8	23
115	Latest Innovations in the Treatment of Venous Disease. Journal of Clinical Medicine, 2018, 7, 77.	3.8	22
116	Short Closure Time Values in PFA–100® Are Related to Venous Thrombotic Risk. Results From the RETROVE Study. Thrombosis Research, 2018, 169, 57-63.	2.9	23
117	Benefits and Risks of Extended Treatment of Venous Thromboembolism With Rivaroxaban or With Aspirin. Thrombosis Research, 2018, 168, 121-129.	2.9	10
118	Reducing the Burden of Venous Thromboembolism in the Acute Medically Ill Population With Extended-Duration Thromboprophylaxis. European Heart Journal Supplements, 2018, 20, E6-E11.	2.9	4
119	Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1315-1321.	2.2	46
120	Quelle durée de traitement après un événement thromboembolique veineux ?. Revue De Medecine Interne, 2018, 39, 839-841.	0.5	0
121	Great Debates in Vascular Medicine: Extended Duration Anticoagulation for Unprovoked Venous Thromboembolism – Coming to Consensus When the Debate Rages On. Vascular Medicine, 2018, 23, 384-387.	2.3	8
122	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. Cancers, 2018, 10, 271.	5.3	37
123	An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy. Clinics in Chest Medicine, 2018, 39, 583-593.	3.2	11
124	Association of Intracranial Hemorrhage Risk With Non–Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-Analysis. JAMA Neurology, 2018, 75, 1511-1518.	22.0	25
125	Invited Commentary. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 583-584.	2.6	2
126	Rivaroxaban in the Cardiovascular World: A Direct Anticoagulant Useful to Prevent Stroke and Venous and Arterial Thromboembolism. Expert Review of Cardiovascular Therapy, 2018, 16, 501-514.	2.7	5

#	Article	IF	Citations
127	Hypercoagulable States and Thrombophilias: Risks Relating to Recurrent Venous Thromboembolism. Seminars in Interventional Radiology, 2018, 35, 99-104.	1.1	18
128	Novel Anticoagulant Treatment for Pulmonary Embolism With Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice. Seminars in Interventional Radiology, 2018, 35, 83-91.	1.1	8
129	Extended Anticoagulation for Unprovoked Venous Thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 529-534.	3.3	6
130	Review of the British Thoracic Society Winter Meeting 2017, 6–8 December 2017, London, UK. Thorax, 2018, 73, 872-876.	7.6	0
131	Updates in Venous Thromboembolism Management: Evidence Published in 2017. Hospital Practice (1995), 2018, 46, 183-188.	1.2	1
132	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Provoked Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2018, 46, 339-345.	2.2	11
133	Landmark Trials in Thrombotic Vascular Disease: A Critical Appraisal of Potential Practice-Changing Trials in 2016–2017. Internal and Emergency Medicine, 2019, 14, 355-363.	4.8	1
134	Statin and All-Cause Mortality in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Data From the RIETE Registry. European Journal of Internal Medicine, 2019, 68, 30-35.	4.2	36
135	Rivaroxaban Versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials Comprising 7,656 Patients. Thrombosis and Haemostasis, 2019, 119, 1517-1526.	4.6	10
136	Definitions, Adjudication, and Reporting of Pulmonary Embolism–Related Death in Clinical Studies: A Systematic Review. Journal of Thrombosis and Haemostasis, 2019, 17, 1590-1607.	5.0	31
137	Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?. Pediatric Cardiology, 2019, 40, 1431-1438.	1.9	9
138	Aktuelle Therapie der akuten Lungenembolie. Pneumologe, 2019, 16, 279-288.	0.2	2
139	Long Term Risk of Symptomatic Recurrent Venous Thromboembolism After Discontinuation of Anticoagulant Treatment for First Unprovoked Venous Thromboembolism Event: Systematic Review and Meta-Analysis. BMJ: British Medical Journal, 2019, 366, l4363.	13.3	287
140	Venous Thromboembolism. Learning Materials in Biosciences, 2019, .	0.0	2
141	Risk Factors for Major Bleeding During Prolonged Anticoagulation Therapy in Patients With Venous Thromboembolism: From the COMMAND VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1498-1507.	4.6	24
142	Rivaroxaban Plus Aspirin for Cardiovascular Protection: Rationale for the Vascular Dose and Dual Pathway Inhibition. Thrombosis Research, 2019, 184, 44-49.	2.9	9
143	Bodyweight-Adjusted Rivaroxaban for Children With Venous Thromboembolism (EINSTEIN-Jr): Results From Three Multicentre, Single-Arm, Phase 2 Studies. Lancet Haematology,the, 2019, 6, e500-e509.	14.9	75
144	ESC-Leitlinien 2019 zu Diagnostik und Management der akuten Lungenembolie. Herz, 2019, 44, 696-700.	1.8	14

#	Article	IF	Citations
145	Fifty Years of Research on Antithrombotic Therapy: Achievements and Disappointments. European Journal of Internal Medicine, 2019, 70, 1-7.	4.2	26
146	Transgender Patients and the Role of the Coagulation Clinician. Journal of Thrombosis and Haemostasis, 2019, 17, 1790-1797.	5.0	41
147	Lungenembolie. Deutsche Medizinische Wochenschrift, 2019, 144, 1286-1300.	0.3	6
148	Using Non-Vitamin K Oral Anticoagulants in Specific Patient Populations: A Study of Korean Cases. Therapeutics and Clinical Risk Management, 2019, 15, 1183-1206.	2.9	7
149	Akute Beinvenenthrombose – moderne Diagnostik und Therapie. Chirurg, 2019, 90, 71-84.	1.0	2
150	Platelets as Central Actors in Thrombosis—Reprising an Old Role and Defining a New Character. Seminars in Thrombosis and Hemostasis, 2019, 45, 802-809.	4.1	21
151	Cost-Effectiveness of Rivaroxaban Versus Apixaban for the Initial Treatment of Venous Thromboembolism and Extended Prevention of Recurrences in the UK. Journal of Medical Economics, 2019, 22, 1179-1191.	3.0	6
152	2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration With the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Respiratory Journal, 2019, 54, 1901647.	11.5	1,306
153	Global Guidelines Trends and Controversies in Lower Limb Venous and Lymphatic Disease. Phlebology, 2019, 34, 4-66.	1.6	77
154	Extended Anticoagulation After Venous Thromboembolism: Should It Be Done?. Therapeutic Advances in Respiratory Disease, 2019, 13, 1753466619878556.	3.4	16
155	Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. Journal of Arthroplasty, 2019, 34, 789-800.e6.	4.7	23
156	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research, 2019, 124, 416-425.	15.7	41
157	Antithrombotic Agents. Circulation Research, 2019, 124, 426-436.	15.7	110
158	Moderne Therapie tiefer Venenthrombosen und der Lungenarterienembolie. Der Internist, 2019, 60, 644-655.	0.7	0
159	Predicting the Risk of Recurrent Venous Thrombosis: What the Future Might Bring. Journal of Thrombosis and Haemostasis, 2019, 17, 1522-1526.	5.0	14
160	Sex Matters: Practice 5P's When Treating Young Women With Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2019, 17, 1417-1429.	5.0	40
161	Real-World Assessment of Off-Label Direct Oral Anticoagulant Dosing for Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 506-510.	2.2	7
162	It's Time for Head-to-Head Trials With Direct Oral Anticoagulants. Thrombosis Research, 2019, 180, 64-69.	2.9	22

#	Article	IF	Citations
163	Extended Anticoagulation for VTE: A Systematic Review and Meta-Analysis. Chest, 2019, 155, 1199-1216.	5.9	36
164	Deep Vein Thrombosis: Update on Diagnosis and Management. Medical Journal of Australia, 2019, 210, 516-524.	3.5	147
165	Decreased Bleeding Incidence With Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients With Sickle Cell Disease and Venous Thromboembolism. Acta Haematologica, 2019, 142, 233-238.	1.7	19
166	Antithrombotic Dose: Some Observations From Published Clinical Trials. British Journal of Clinical Pharmacology, 2019, 85, 2194-2197.	3.0	1
167	Akute Beinvenenthrombose – moderne Diagnostik und Therapie. Gefasschirurgie, 2019, 24, 271-284.	0.4	2
168	Safety of Direct Oral Anticoagulants Versus Traditional Anticoagulants in Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 439-453.	2.2	31
169	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. Seminars in Liver Disease, 2019, 39, 195-208.	4.1	47
170	Mouse Venous Thrombosis Upon Silencing of Anticoagulants Depends on Tissue Factor and Platelets, Not FXII or Neutrophils. Blood, 2019, 133, 2090-2099.	10.6	29
171	Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-Term Treatment. Current Cardiology Reports, 2019, 21, 1-10.	4.5	11
172	Rivaroxaban for the Treatment of Venous Thromboembolism in Real Life: A Single-Center Prospective Study. Medicine (United States), 2019, 98, e14093.	2.1	4
173	Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist: Aspirin or Rivaroxaban for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty. American Journal of Physical Medicine and Rehabilitation, 2019, 98, e40.	2.3	1
174	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. Platelets, 2019, .	3.8	0
175	8. Jahrestagung der Vereinigung der interdisziplinären Gefäßmediziner Süddeutschlands (VIGS). Gefasschirurgie, 2019, 24, 176-181.	0.4	0
176	Real World Experience at a Single Centre Using Low Dose Direct Oral Anticoagulants After Unprovoked Venous Thromboembolism. British Journal of Haematology, 2019, 186, e39-e41.	3.2	1
177	Efficacy and Safety of Xa Inhibitors for the Treatment of Cancer-Associated Venous Thromboembolism. Expert Opinion on Drug Safety, 2019, 18, 313-320.	3.2	5
178	Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. American Journal of Cardiovascular Drugs, 2019, 19, 525-539.	3.7	11
179	Extended Anticoagulation for the Secondary Prevention of Venous Thromboembolic Events: An Updated Network Meta-Analysis. PLoS ONE, 2019, 14, e0214134.	3.2	33
180	Influence of Baseline Anemia on Long-Term Clinical Outcomes in Patients With Venous Thromboembolism: From the COMMAND VTE Registry. Journal of Thrombosis and Thrombolysis, 2019, 47, 444-453.	2.2	13

#	Article	IF	Citations
181	Venous Thromboembolism: A Clinician Update. Vascular Medicine, 2019, 24, 122-131.	2.3	33
182	Anticoagulation Risk Assessment for Patients With Non-Valvular Atrial Fibrillation and Venous Thromboembolism: A Clinical Review. Vascular Medicine, 2019, 24, 141-152.	2.3	12
183	Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism. Mayo Clinic Proceedings, 2019, 94, 1242-1252.	3.7	38
184	Long-Term Management of Venous Thromboembolism: Lessons From EINSTEIN CHOICE and Other Extension Trials. Thrombosis and Haemostasis, 2019, 119, 689-694.	4.6	16
185	Venous Thromboembolism and Cancer: Current and Future Role of Direct-Acting Oral Anticoagulants. Thrombosis Research, 2019, 177, 33-41.	2.9	17
186	New Guidelines From the Thrombosis and Haemostasis Society of Australia and New Zealand for the Diagnosis and Management of Venous Thromboembolism. Medical Journal of Australia, 2019, 210, 227-235.	3.5	127
187	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer. New England Journal of Medicine, 2019, 380, 720-728.	76.6	691
188	Rivaroxaban for Prevention and Treatment of Venous Thromboembolism. Future Cardiology, 2019, 15, 63-77.	1.2	9
189	Use of Rivaroxaban in Patients Attending a Hematology Unit in Clinical Practice. Future Cardiology, 2019, 15, 347-353.	1.2	0
190	Patients With High Levels of Circulating Endothelial Progenitor Cells (EPC) Following at Least Three Months of Anticoagulation for Unprovoked Venous Thromboembolism (VTE) Are at Low Risk of Recurrent VTE—Results From the ExACT Randomised Controlled Trial. EClinicalMedicine, 2019, 17, 100218.	13.5	9
191	Rivaroxaban and the EINSTEIN Clinical Trial Programme. Blood Coagulation and Fibrinolysis, 2019, 30, 85.	1.0	33
192	Prevention of Postpartum Venous Thromboembolism. Obstetrical and Gynecological Survey, 2019, 74, 601.	0.1	7
193	Impact of Prolonged Anticoagulation With Rivaroxaban on Provoked Venous Thromboembolism Recurrence: Improve-VTE. American Journal of Medicine, 2019, 132, 498-504.	3.2	7
194	Effectiveness and Safety of Apixaban Versus Rivaroxaban for Prevention of Recurrent Venous Thromboembolism and Adverse Bleeding Events in Patients With Venous Thromboembolism: A Retrospective Population-Based Cohort Analysis. Lancet Haematology,the, 2019, 6, e20-e28.	14.9	78
195	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038.	4.6	31
196	Utility of the DASH Score After Unprovoked Venous Thromboembolism; A Single Centre Study. British Journal of Haematology, 2019, 185, 631-633.	3.2	9
197	Bleeding Rates of Veterans Taking Apixaban or Rivaroxaban for Atrial Fibrillation or Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 47, 280-286.	2.2	7
198	Behçet's Syndrome as a Tool to Dissect the Mechanisms of Thrombo-Inflammation: Clinical and Pathogenetic Aspects. Clinical and Experimental Immunology, 2019, 195, 322-333.	4.3	62

#	Article	IF	Citations
199	Six Months Versus Two Years of Oral Anticoagulation After a First Episode of Unprovoked Deep-Vein Thrombosis. The PADIS-DVT Randomized Clinical Trial. Haematologica, 2019, 104, 1493-1501.	3.9	39
200	Anticoagulation in Patients With Embolic Stroke of Unknown Source. International Journal of Stroke, 2019, 14, 334-336.	7.4	10
201	Extended Treatment of Venous Thromboembolism: A Systematic Review and Network Meta-Analysis. Heart, 2019, 105, 545-552.	4.9	37
202	Acute Pulmonary Embolism: A Concise Review of Diagnosis and Management. Internal Medicine Journal, 2019, 49, 15-27.	1.6	80
203	Incidence, Mortality and Bleeding Rates Associated With Pulmonary Embolism in England Between 1997 and 2015. International Journal of Cardiology, 2019, 277, 229-234.	3.2	41
204	Rivaroxaban for Left Ventricular Thrombus. American Journal of Therapeutics, 2019, 26, e511.	1.1	6
205	Which Patients With Unprovoked Venous Thromboembolism Should Receive Extended Anticoagulation With Direct Oral Anticoagulants? A Systematic Review, Network Meta-Analysis, and Decision Analysis. Journal of Evaluation in Clinical Practice, 2020, 26, 7-17.	1.9	9
206	Morbidly Obese Patient on Rivaroxaban Presents With Recurrent Upper Extremity Deep Vein Thrombosis: A Case Report. Journal of Pharmacy Practice, 2020, 33, 712-719.	1.3	4
207	Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis. Angiology, 2020, 71, 27-37.	2.4	22
208	Extending Venous Thromboembolism Secondary Prevention With Apixaban in Cancer Patients: The EVE Trial. European Journal of Haematology, 2020, 104, 88-96.	2.9	34
209	Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 792-799.e61.	10.5	79
210	2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration With the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 543-603.	14.7	4,722
211	A Randomised Controlled Trial of Extended Anticoagulation Treatment Versus Standard Treatment for the Prevention of Recurrent Venous Thromboembolism (VTE) and Post-Thrombotic Syndrome in Patients Being Treated for a First Episode of Unprovoked VTE (the ExACT Study). British Journal of Haematology, 2020, 188, 962-975.	3.2	37
212	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Annals of Emergency Medicine, 2020, 76, 470-485.	3.8	85
213	Partial Rescue of Naturally Occurring Active Site Factor X Variants Through Decreased Inhibition by Tissue Factor Pathway Inhibitor and Antithrombin. Journal of Thrombosis and Haemostasis, 2020, 18, 136-150.	5.0	3
214	Venous Thromboembolism in Heart Failure Patients: Pathophysiology, Predictability, Prevention. Journal of the American College of Cardiology, 2020, 75, 159-162.	12.0	33
215	Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thrombosis and Haemostasis, 2020, 120, 014-026.	4.6	18
216	The Dual Role of Platelet-Innate Immune Cell Interactions in Thrombo-Inflammation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 23-35.	3.3	180

#	Article	IF	Citations
217	Reply. Gastroenterology, 2020, 158, 285-286.	12.5	0
218	Does Cell-Free DNA Promote Coagulation and Inhibit Fibrinolysis in Patients With Unprovoked Venous Thromboembolism?. Thrombosis Research, 2020, 186, 13-19.	2.9	17
219	Long-Term Mortality After Massive, Submassive, and Low-Risk Pulmonary Embolism. Vascular Medicine, 2020, 25, 141-149.	2.3	64
220	Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine. Chirurgische Gastroenterologie Interdisziplinar, 2020, 36, 280-287.	1.7	9
221	American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Blood Advances, 2020, 4, 4693-4738.	6.3	1,378
222	Analysis of the Quality of Reporting of Randomized Controlled Trials in Anticoagulant Versus Antiplatelet Medication for Venous Thromboembolism Prophylaxis as Governed by the CONSORT Statement. Journal of Thrombosis and Thrombolysis, 2021, 52, 138-147.	2.2	3
223	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 1076029620945792.	2.2	13
224	Anticoagulants oraux directs : dans quelles indications ? Lequel prescrire ? Pour ou contre chez les personnes fragiles et dans les situations atypiques ? Quelle surveillance et gestion des accidents hémorragiques ?. Revue De Medecine Interne, 2020, 41, 598-606.	0.5	5
225	Direct Oral Anticoagulants: Evidence and Unresolved Issues. Lancet, The, 2020, 396, 1767-1776.	96.9	180
226	Utilize the Full Potential of Real World Evidence. European Journal of Internal Medicine, 2020, 82, 27-28.	4.2	0
227	Prevention of Venous Thromboembolism in Ambulatory Patients With Cancer. ESMO Open, 2020, 5, e000948.	8.4	24
228	Does Aspirin Prevent Venous Thromboembolism?. Hematology, 2020, 2020, 634-641.	2.5	44
229	Evidence-Based Minireview: Abnormal Uterine Bleeding in Users of Rivaroxaban and Apixaban. Hematology, 2020, 2020, 538-541.	2.5	28
230	Which Patients Are at High Risk of Recurrent Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism)?. Blood Advances, 2020, 4, 5595-5606.	6.3	51
231	Is Aspirin Safer Than a Direct Oral Anticoagulant for Patients With Atrial Fibrillation at High Risk of Bleeding?. European Journal of Internal Medicine, 2020, 79, 25-26.	4.2	1
232	Aspirin and Low-Dose Rivaroxaban – The Dual Pathway Concept in Patients With Stable Atherosclerotic Disease: A Comprehensive Review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	2.7	3
233	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients With COVID-19 ?. Drugs, 2020, 80, 1383-1396.	15.5	98
234	Pulmonary Embolism: Update on Management and Controversies. BMJ, The, 2020, 370, m2177.	11.6	206

#	Article	IF	Citations
235	Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. JAMA - Journal of the American Medical Association, 2020, 324, 1765-1776.	37.0	241
236	Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. Journal of the American College of Cardiology, 2020, 76, 2142-2154.	12.0	49
237	Preparation of Amphiphilic Magnetic Polyvinyl Alcohol Targeted Drug Carrier and Drug Delivery Research. Designed Monomers and Polymers, 2020, 23, 197-206.	2.3	10
238	Descriptive Study of the General Practitioners' Perception of Direct Oral Anticoagulants and the Risk of Genital Bleeding in Women of Childbearing Age. JMV-Journal De Medecine Vasculaire, 2020, 45, 198-209.	1.2	1
239	Rationale and Design of a Prospective, Observational, Multicentre Study on the Safety and Efficacy of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias: The PROTECT-AR Study. BMJ Open, 2020, 10, e038012.	2.7	8
240	Rivaroxaban for the Treatment of Venous Thromboembolism in Pediatric Patients. Expert Review of Cardiovascular Therapy, 2020, 18, 733-741.	2.7	17
241	Pulmonary Embolism. Respiratory Medicine, 2020, .	0.0	1
242	Antithrombotische Therapie Bei Lungenembolie. Deutsche Medizinische Wochenschrift, 2020, 145, 970-977.	0.3	2
243	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 1076029620945398.	2.2	5
244	Updates on the Use of Direct Oral Anticoagulants for the Management of Chronic Conditions. Pharmacy Today, 2020, 26, 44-58.	0.0	0
245	Which Patients Are at High Risk of Recurrent Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism)?. Hematology, 2020, 2020, 201-212.	2.5	18
246	Bleeding Risk in Patients With Venous Thromboembolic Events Treated With New Oral Anticoagulants. Journal of Thrombosis and Thrombolysis, 2021, 52, 315-323.	2.2	14
247	Tumorassoziierte venöse Thromboembolie – Pathogenese, Diagnose, Prävention und Therapie. Best Practice Onkologie, 2020, 15, 448-455.	0.1	2
248	Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-Analysis. TH Open, 2020, 04, e80-e93.	1.8	19
249	Treatment of Acute Venous Thromboembolism. Medical Clinics of North America, 2020, 104, 631-646.	5.3	2
250	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Thrombosis and Haemostasis, 2020, 120, 805-814.	4.6	18
251	Treatment of Venous Thromboembolism in Special Populations With Direct Oral Anticoagulants. Thrombosis and Haemostasis, 2020, 120, 899-911.	4.6	23
252	Bleeding Risk Comparison Between Direct Oral Anticoagulants at Doses Approved for Atrial Fibrillation and Aspirin: Systematic Review, Meta-Analysis and Meta-Regression. European Journal of Internal Medicine, 2020, 79, 31-36.	4.2	13

#	Article	IF	Citations
253	Management of Acute Pulmonary Embolism 2019: What Is New in the Updated European Guidelines?. Internal and Emergency Medicine, 2020, 15, 957-966.	4.8	19
254	Special Considerations in Pulmonary Embolism: Clot-in-Transit and Incidental Pulmonary Embolism. Critical Care Clinics, 2020, 36, 531-546.	3.3	18
255	Long Term Use of Anticoagulant Therapy for Patients With Pulmonary Embolism. Expert Review of Hematology, 2020, 13, 709-718.	2.7	1
256	Tratamiento de la trombosis venosa profunda de extremidades inferiores. Revista Clinica Espanola, 2020, 220, 57-68.	0.3	2
257	Patient Satisfaction After Conversion From Warfarin to Direct Oral Anticoagulants for Patients on Extended Duration of Anticoagulation for Venous Thromboembolism – The SWAN Study. PLoS ONE, 2020, 15, e0234048.	3.2	13
258	Challenges and Opportunities in the Pharmacological Treatment of Acute Venous Thromboembolism in Children. Paediatric Drugs, 2020, 22, 385-397.	4.6	9
259	Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients With Extremes in Bodyweight. European Journal of Haematology, 2020, 105, 484-494.	2.9	23
260	Extended DOAC Therapy in Patients With VTE and Potential Risk of Recurrence: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2308-2317.	5.0	17
261	Review of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty. Geriatrics (Switzerland), 2020, 5, 18.	2.7	15
262	Impact of Concomitant Antiplatelet Therapy on the Efficacy and Safety of Direct Oral Anticoagulants for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1661-1671.	5.0	21
263	Therapeutic Strategies for Thrombosis: New Targets and Approaches. Nature Reviews Drug Discovery, 2020, 19, 333-352.	91.0	387
264	Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. TH Open, 2020, 04, e119-e126.	1.8	6
265	Effect of Tailoring Anticoagulant Treatment Duration by Applying a Recurrence Risk Prediction Model in Patients With Venous Thromboembolism Compared to Usual Care: A Randomized Controlled Trial. PLoS Medicine, 2020, 17, e1003142.	8.4	20
266	Oral Factor Xa Inhibitors and Risk of Subdural Hematoma. Neurology, 2020, 95, e480-e487.	5.0	1
267	Prognosis and Risk Factors in Older Patients With Lung Cancer and Pulmonary Embolism: A Propensity Score Matching Analysis. Scientific Reports, 2020, 10, 1-8.	5.2	24
268	Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention. Neurology, 2020, 94, 876-885.	5.0	194
269	Managing Thromboembolic Risk in Patients With Hereditary and Acquired Thrombophilias. Blood, 2020, 135, 344-350.	10.6	38
270	Retrospective Review of d-Dimer Testing for Venous Thrombosis Recurrence Risk Stratification: Is This a Useful Test in the Real World?. Journal of Thrombosis and Thrombolysis, 2020, 49, 562-571.	2.2	5

#	Article	IF	Citations
271	Kommentar zu den Leitlinien (2019) der European Society of Cardiology zum Management der akuten Lungenembolie. Kardiologe, 2020, 14, 248-255.	0.5	9
272	Aktuelles Management der Lungenembolie. CardioVasc, 2020, 20, 16-23.	0.0	1
273	Extended Oral Anticoagulation After Incident Venous Thromboembolism – A Paradigm Shift?. Expert Review of Cardiovascular Therapy, 2020, 18, 201-208.	2.7	3
274	Long-Term Treatment of Venous Thromboembolism. Blood, 2020, 135, 317-325.	10.6	98
275	Design and Rationale of a Randomized, Placebo-Controlled Trial on the Efficacy and Safety of Sulodexide for Extended Treatment in Elderly Patients After a First Venous Thromboembolism. Internal and Emergency Medicine, 2021, 16, 359-368.	4.8	6
276	An International Survey of Clinicians Regarding Their Management of Venous Thromboembolism Following the Initial 3–6 Months of Anticoagulation. Journal of Thrombosis and Thrombolysis, 2021, 51, 17-24.	2.2	6
277	Lower Dose Direct Oral Anticoagulants and Improved Survival: A Combined Analysis in Patients With Established Atherosclerosis. European Journal of Internal Medicine, 2021, 83, 14-20.	4.2	9
278	Direct Oral Anticoagulants in Patients With Severe Inherited Thrombophilia: A Single-Center Cohort Study. International Journal of Hematology, 2021, 113, 190-198.	2.0	15
279	Influence of Low Body Weight on Long-Term Clinical Outcomes in Patients With Venous Thromboembolism: From the COMMAND VTE Registry. Thrombosis Research, 2021, 198, 26-33.	2.9	11
280	Prediction and Treatment of Bleeding in Patients Under Anticoagulant Treatment. Medicina Clínica (English Edition), 2021, 156, 20-25.	0.2	1
281	Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery, 2021, 61, 9-82.	3.2	720
282	Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction Be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	4.1	2
283	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 2021, 77, 629-658.	12.0	299
284	Predicción y tratamiento de la hemorragia en pacientes anticoagulados. Medicina Clínica, 2021, 156, 20-25.	1.2	3
285	Decision-Making in the Management of Venous Thromboembolism. American Journal of Medicine, 2021, 134, 317-325.	3.2	2
286	Management of Venous Thromboembolism in Athletes. Blood Reviews, 2021, 47, 100780.	7.6	8
287	Risk of Venous Thromboembolism in Rheumatoid Arthritis. Joint Bone Spine, 2021, 88, 105122.	3.2	54
288	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. American Journal of Cardiovascular Drugs, 2021, 21, 283-297.	3.7	14

#	Article	IF	Citations
289	Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center. Thrombosis and Haemostasis, 2021, 121, 242-245.	4.6	6
290	Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?. Revue Des Maladies Respiratoires, 2021, 38, e99-e112.	0.3	5
291	Thromboses Veineuses Distales et Superficielles. , 2021, .		0
292	Thromboembolism in Older Adults. Frontiers in Medicine, 2021, 7, 470016.	3.7	16
293	Pathway for the Diagnosis and Management of Pulmonary Embolism. Critical Pathways in Cardiology, 2021, 20, 57.	1.0	2
294	Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review. Cardiovascular Therapeutics, 2021, 2021, 8886210.	3.0	28
295	Clinical Indications for Direct Acting Oral Anticoagulants. , 2021, .		0
296	Towards Personalized Antithrombotic Management With Drugs and Devices Across the Cardiovascular Spectrum. European Heart Journal, 2022, 43, 940-958.	14.7	18
297	Pulmonary Embolism. , 2021, .		0
298	Heavy Menstrual Bleeding in Women on Anticoagulant Treatment for Venous Thromboembolism: Comparison of High- and Low-Dose Rivaroxaban With Aspirin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 308-313.	3.3	14
299	COVID-19 and Its Implications for Thrombosis and Anticoagulation. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 316-326.	3.4	25
300	Prevention of Recurrent Thromboembolism in Myeloproliferative Neoplasms: Review of Literature and Focus on Direct Oral Anticoagulants. Postgraduate Medicine, 2021, 133, 508-516.	3.0	6
301	Rivaroxaban Versus Aspirin in Prevention of Venous Thromboembolism Following Total Joint Arthroplasty or Hip Fracture Surgery: A Meta-Analysis. Journal of Orthopaedic Surgery and Research, 2021, 16, 1-7.	4.0	19
302	Диагностика и лечение тромбоэмболии лёгочной артерии: Клинические рекомендации евразийской ассоциации кардиологов для практических врачей (2021). Eurasian Heart Journal, 2021, 0, 44-77.	0.9	32
303	Provoked Versus Unprovoked Venous Thromboembolism: Findings From GARFIELD-VTE. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 326-341.	3.3	41
304	Primary Prophylaxis of Venous Thromboembolic Disease With Direct Oral Anticoagulants in Patients With Severe Inherited Thrombophilia. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 261-264.	3.3	3
305	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 218-232.	3.4	5
306	Risk of Intracranial Hemorrhage With Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Neurology, 2022, 269, 664-675.	5.4	39

#	Article	IF	Citations
307	Anticoagulant Treatment for Venous Thromboembolism: A Pooled Analysis and Additional Results of the XALIA and XALIA-LEA Noninterventional Studies. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 426-438.	3.3	18
308	Management of Patients With Venous Thromboembolism After the Initial Treatment Period. Journal of the American Board of Family Medicine, 2021, 34, 409-419.	1.9	5
309	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. Journal of Clinical Pharmacology, 2021, 61, 1010-1026.	2.4	25
310	Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation With Vitamin K Antagonists for Venous Thromboembolism. Thrombosis and Haemostasis, 2021, 121, 1512-1522.	4.6	20
311	Delayed Anticoagulation in Venous Thromboembolism: Reasons and Associated Outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12500.	3.3	8
312	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	8.4	1,074
313	Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2847.	1.4	13
314	Impact of Oral Anticoagulant Choice for the Secondary Prevention of Venous Thromboembolism on the Risk of Inpatient Bleeding. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12514.	3.3	5
315	Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients With COVID-19: The PREVENT-HD Study. American Heart Journal, 2021, 235, 12-23.	3.3	40
316	Stroke Prevention: Little-Known and Neglected Aspects. Cerebrovascular Diseases, 2021, 50, 622-635.	2.1	13
317	A Case of Acute Pulmonary Embolism With Severe Haemoptysis. Thrombosis Research, 2021, 208, 199-201.	2.9	5
318	Are the Correct Outcomes Being Measured in Studies of Oral Anticoagulants? A Systematic Survey. Thrombosis Research, 2021, 201, 30-49.	2.9	4
319	Antithrombotics and New Interventions for Venous Thromboembolism: Exploring Possibilities Beyond Factor IIa and Factor Xa Inhibition. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12509.	3.3	13
320	Diseases of the Cardiovascular System. , 2021, .		20
321	Review Article: Gastrointestinal Bleeding Risk With Direct Oral Anticoagulants. Cardiovascular Drugs and Therapy, 2022, 36, 973-989.	4.1	44
322	Cancer and Thrombosis: New Treatments, New Challenges. Medical Sciences, 2021, 9, 41.	6.3	7
323	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2021, 47, 800-814.	4.1	23
324	Профилактика десинхроноза в спорте. Sports Medicine Research and Practice, 2021, 11, 79-90.	0.7	1

#	Article	IF	Citations
325	Place actuelle des anticoagulants oraux directs dans la maladie thromboembolique veineuse. Revue De Medecine Interne, 2022, 43, 82-88.	0.5	2
326	Evaluation of Prescribing Practices and Outcomes Using Direct-Acting Oral Anticoagulants After Cardiac Surgery. Clinical Therapeutics, 2021, 43, e209-e216.	3.4	2
327	Anticoagulant-Associated Gastrointestinal Bleeding: Framework for Decisions About Whether, When and How to Resume Anticoagulants. Journal of Thrombosis and Haemostasis, 2021, 19, 2383-2393.	5.0	49
328	Diagnostic Accuracy of D-Dimer Testing for Recurrent Venous Thromboembolism: A Systematic Review With Meta-Analysis.: VTE Recurrence and D-Dimer. European Journal of Internal Medicine, 2021, 89, 39-47.	4.2	26
329	Venous Thromboembolism. Lancet, The, 2021, 398, 64-77.	96.9	715
330	Characteristics of Patients Receiving Extended Treatment After Incident Venous Thromboembolism. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 332-342.	3.9	5
331	Unprovoked or Provoked Venous Thromboembolism: Not the Prevalent Criterion to Decide on Anticoagulation Extension in Clinical Practice of Various Countries—The Prospective, International, Observational WHITE Study. Internal and Emergency Medicine, 2022, 17, 71-82.	4.8	9
332	Use of Direct Oral Anticoagulants in Patients With Obesity for Treatment and Prevention of Venous Thromboembolism: Updated Communication From the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 1874-1882.	5.0	245
333	Prophylactic Anticoagulation in Sinus Rhythm for Stroke Prevention in Cardiovascular Disease: Contemporary Meta-Analysis of Large Randomized Trials. European Journal of Preventive Cardiology, 2022, 28, 1939-1948.	6.1	1
334	Second Consensus Document on Diagnosis and Management of Acute Deep Vein Thrombosis: Updated Document Elaborated by the ESC Working Group on Aorta and Peripheral Vascular Diseases and the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. European Journal of Preventive Cardiology, 2022, 29, 1248-1263.	6.1	122
335	Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Mayo Clinic Proceedings, 2021, 96, 2793-2805.	3.7	40
336	Long-Term Risk of Recurrent Venous Thromboembolism Among Patients Receiving Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	5.0	35
337	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest, 2021, 160, e545-e608.	5.9	1,025
338	Reduced-Dose Direct Oral Anticoagulants (DOACs) in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis—Response to Commentary. Journal of Thrombosis and Haemostasis, 2021, 19, 2359-2360.	5.0	6
339	Qual droga utilizar para o tratamento prolongado de tromboembolismo venoso?. Revista Da Faculdade De Ciências Médicas De Sorocaba, 2021, 22, 85.	0.1	0
340	Venous Thrombosis Recurrence Risk According to Warfarin Versus Direct Oral Anticoagulants for the Secondary Prevention of Venous Thrombosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12575.	3.3	4
341	Half-Dose Anticoagulation for Venous Thromboembolism and Phlegmasia Cerulea Dolens in a Patient With Recurrent Subdural Hematoma. Cureus, 2021, 13, e18048.	1.3	1
342	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	12.9	140

#	Article	IF	Citations
343	The Effect of Anticoagulant in Patients With Cirrhosis Associated With Acute Portal Vein Thrombosis. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 177-182.	1.0	0
344	Direct Oral Anticoagulant Dose Selection: Challenging Cases. Journal of Thrombosis and Haemostasis, 2021, 19, 2680-2686.	5.0	6
345	Venous Thromboembolism: Recent Advancement and Future Perspective. Journal of Cardiology, 2022, 79, 79-89.	3.8	81
346	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients With Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. Thrombosis and Haemostasis, 2022, 122, 1061-1070.	4.6	14
347	Tromboembolismo Pulmonar. Medicine, 2021, 13, 2371-2378.	0.1	0
348	When and How to Use Direct Oral Anticoagulants in Patients With Advanced Chronic Liver Disease?. Current Opinion in Pharmacology, 2021, 60, 111-116.	5.3	8
349	Risque de maladie thromboembolique veineuse dans la polyarthrite rhumatoïde. Revue Du Rhumatisme, 2021, 88, 338-345.	0.0	0
350	Impact of Direct Oral Anticoagulants on Evolution of Post-Thrombotic Syndrome. Thrombosis Research, 2021, 207, 10-15.	2.9	2
351	Encyclopedia of Respiratory Medicine. , 2022, .		332
352	Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thrombosis and Haemostasis, 2021, 121, 816-825.	4.6	43
353	Assessment of a Pharmacist-Led Direct Oral Anticoagulant Monitoring Clinic. Canadian Journal of Hospital Pharmacy, 2021, 74, 7-14.	0.6	12
354	The 2019 European Guidelines on Pulmonary Embolism Illustrated With the Aid of an Exemplary Case Report. European Heart Journal - Case Reports, 2021, 5, ytaa542.	0.6	3
355	Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. Hemato, 2021, 2, 64-78.	0.9	5
356	Arzneiverordnungs-Report 2018. , 2018, .		64
357	French Vascular Physicians' Practices in Indicating Antiplatelet and Anticoagulation Therapy in Venous Thromboembolism. Vasa - European Journal of Vascular Medicine, 2019, 48, 355-360.	2.7	3
358	A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (the J'xactly Study). Circulation Journal, 2020, 84, 1912-1921.	4.0	23
359	Recent Advances in Understanding, Diagnosing and Treating Venous Thrombosis. F1000Research, 2020, 9, 1206.	1.1	12
360	Highlights From ACC.17 Scientific Sessions. Anatolian Journal of Cardiology, 2017, 17, 351-352.	1.3	1

#	Article	IF	Citations
361	Dynamics of Coagulation Parameters and Their Relationship With Venous Thromboembolic Eventsin Patients With Cardiac Implantable Electronic Devices. Flebologiya, 2019, 13, 21.	1.4	5
362	Diagnostics and Treatment of Superficial Trombophlebitis. Guidelines of the Russian PhlebologicalAssociation. Flebologiya, 2019, 13, 78.	1.4	29
363	Pathogenesis and Prevention of Venous and Arterial Thromboembolic Events in Patients After Deep Vein Thrombosis of Lower Extremities. Khirurgiya, 2018, .	0.5	1
364	Contemporary Approaches to Determine the Duration of Anticoagulant Therapy for Venous Thromboembolism. Khirurgiya, 2019, .	0.5	5
365	Выбор лечебной тактики при тромбоэмболии легочной артерии средневысокого риска и хронической болезни почек. Kardiologiya, 2019, 59, 88-96.	0.9	2
366	Venous Thromboembolism: Current Management. Australian Prescriber, 2019, 42, 123-126.	1.8	14
367	Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants. Current Pharmaceutical Design, 2020, 26, 2692-2702.	3.4	13
368	Lungenarterienembolie: Status 2018. Deutsches Ärzteblatt International, 2018, .	3.5	5
369	Update on the Management of Venous Thromboembolism. Cleveland Clinic Journal of Medicine, 2017, 84, 39-46.	2.4	78
370	Evaluation of the Safety and Effectiveness of Direct Oral Anticoagulants and Low Molecular Weight Heparin in Gastrointestinal Cancer-Associated Venous Thromboembolism. World Journal of Gastrointestinal Oncology, 2019, 11, 866-876.	2.5	16
371	Superficial Phlebitis and Thrombophlebitis. Flebologiya, 2021, 15, 211-244.	1.4	22
372	Rivaroxaban in the Treatment and Long-Term Prevention of Recurrent VTEC in Patients With Pulmonary Embolism. Flebologiya, 2021, 15, 199-204.	1.4	2
373	Lungenembolie. Pneumologie, 2021, 75, 800-818.	0.9	3
374	Bleeding Risks With Novel Oral Anticoagulants Especially Rivaroxaban Versus Aspirin: A Meta-Analysis. Thrombosis Journal, 2021, 19, 1-11.	2.9	15
375	Venous Thromboembolism for the Practicing Cardiologist. Cardiology Clinics, 2021, 39, 551-566.	1.4	1
376	Current Tendencies in the Prevention of Recurrent Venous Thromboembolism. Flebologiya, 2017, 11, 83.	1.4	0
377	Rivaroxaban Ist Wirksamer Als Aspirin Bei Verhinderung Erneuter Venöser Thromboembolien. Praxis, 2017, 106, 727-728.	0.3	0
378	Apixaban již více než dva roky dostupný v léčbě žilní trombembolické nemoci. Klinicka Farmakologie A Farmacie, 2017, 31, 23-26.	0.3	0

#	Article	IF	Citations
379	5. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1875-1881.	0.0	0
380	Comparing the Efficacy, Safety and Cost of the Anticoagulants: Rivaroxaban and Nadroparin in Hip Replacement Surgery. International Journal of Pharmacology, 2017, 14, 1-8.	0.5	6
381	The Year in Cardiology 2017: Prevention. Cardiologia Croatica, 2018, 13, 79-98.	0.0	0
382	The Year 2017 in Cardiology: Aorta and Peripheral Circulation. Cardiologia Croatica, 2018, 13, 99-109.	0.0	1
383	The Optimal Duration and Selection of Anti-Coagulants After First Episode of Unprovoked Venous Thromboembolism. Clinical & Experimental Thrombosis and Hemostasis, 2018, 4, 1-6.	0.0	0
384	EINSTEIN-CHOICE Trial – Rationale for the Extended Anticoagulation in Secondary Prevention. Vasa - European Journal of Vascular Medicine, 2018, 47, 333-334.	2.7	0
385	Przewlekłe Leczenie Przeciwkrzepliwe. Acta Haematologica Polonica, 2018, 49, 47-49.	0.3	1
386	Современная тактика лечения и профилактики венозных тромбозов и тромбоэмболий. Роль новых пероральных антикоагулянтов. Часть II. Emergency Medical Care, 2018, 18, 60-65.	0.2	1
387	Anticoagulants and Treatment of Venous Thromboembolism. , 2019, .		0
388	The Saint-Chopra Guide to Inpatient Medicine. , 2018, .		8
389	Extended Anticoagulant Therapyin Patients, Who Survived Pulmonary Embolism. Atherothrombosis, 2018, .	0.5	0
390	Prolonged Anticoagulation Therapy for Venous Thromboembolism: Resolved Issuesand Controversial Questions. Flebologiya, 2019, 13, 42.	1.4	3
391	Recirculation Syndrome in Hemodialysis Patients. Khirurgiya, 2019, .	0.5	0
392	Consultative Hemostasis and Thrombosis. , 2019, .		68
393	Возможности применения апиксабана на разных этапах ведения больных с тромбоэмболией легочной артерии. Meditsinskiy Sovet, 2019, 0, 8-15.	0.4	0
394	2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. Korean Journal of Medicine, 2019, 94, 57-82.	0.3	1
395	Cardioembolic Stroke, the Basis of Diagnosis and Prevention. Medical Almanac, 2019, .	0.2	1
396	Oxidative Stress as a Thrombophilic Factor in Behçet Syndrome. , 2020, .		0

#	Article	IF	Citations
397	Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists. European Journal of Case Reports in Internal Medicine, 2019, 6, 001310.	0.6	9
398	Noninvasive Vascular Diagnosis. , 2020, .		14
399	Recent Advances in Preventing Recurrent Stroke. F1000Research, 2020, 9, 1012.	1.1	1
400	Management of the Acute Thrombus-Bearing IVC Filter. , 2020, .		1
401	Extended Therapy and Secondary Prevention of Venous Thromboembolic Complications. I P Pavlov Russian Medical Biological Herald, 2020, 28, 548-566.	0.9	0
402	Thrombosis With Thrombocytopenia - A Vascular Paradox. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 3110-3116.	0.0	0
403	Venous Thromboembolism. Journal of the Australasian Society of Aerospace Medicine, 2021, 12, 1-6.	0.3	0
404	Kompendium Internistische Onkologie. Springer Reference Medizin, 2020, .	0.0	15
405	Outpatient Treatment for Deep Vein Thrombosis With Rivaroxaban: A Single-Center Experience. Flebologiya, 2020, 14, 99-106.	1.4	5
406	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	16
407	Post-PE Management. Respiratory Medicine, 2020, .	0.0	0
408	Results of Treatment With Oral Anticoagulants in Patients With Lower Limb Deep Vein Thrombosis. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2020, 26, 42-50.	0.2	1
409	Rivaroxaban Use in the Treatment of Patients With Deep Vein Thrombosis or Pulmonary Embolism. Atherothrombosis, 2020, .	0.5	0
410	Erkrankungen der Gefässe. , 2020, .		0
411	Current Concepts of Anticoagulant and Antiplatelet Therapy in Patients With Vascular Pathology. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2020, 26, 16-26.	0.2	1
412	Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review. Cureus, 2021, 13, e18992.	1.3	29
413	Efficacy and Safety of Rivaroxaban in Cerebral Venous Thrombosis: Insights From a Prospective Cohort Study. Journal of Thrombosis and Thrombolysis, 2022, 53, 594-600.	2.2	16
414	Practice Patterns and Outcomes of Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. Blood Cancer Journal, 2021, 11, 1-7.	11.1	26

#	Article	IF	Citations
415	VTE and Anticoagulation in Menstruating Women. Thrombosis Update, 2021, 5, 100088.	1.6	3
416	Anticoagulation for Patients With Venous Thromboembolism: When Is Extended Treatment Required?. TH Open, 2020, 04, e446-e456.	1.8	20
417	Venous Thromboembolism. , 2021, .		0
418	Pulmonary Embolism. , 2022, .		11
419	Aspirin Relieves the Calcification of Aortic Smooth Muscle Cells by Enhancing the Heat Shock Response. Pharmaceutical Biology, 2022, 60, 17-24.	6.3	14
420	Long-Term Risk of Major Bleeding After Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 1186-1197.	4.6	11
421	Extended Anticoagulation Treatment for Cancer-Associated Thrombosis—Rates of Recurrence and Bleeding Beyond 6 Months: A Systematic Review. Journal of Thrombosis and Haemostasis, 2022, 20, 619-634.	5.0	61
422	Can I Stop Anticoagulation When Cancer Is in Remission?. Circulation Journal, 2022, 86, 934-935.	4.0	0
423	Author's Reply: Re: Comparison of Anticoagulation Regimens Following Stent Placement for Nonthrombotic Lower Extremity Venous Disease. Journal of Vascular and Interventional Radiology, 2022, 33, 341-342.	2.2	0
424	Diagnostik und Therapie der Lungenembolie. Herz, 2021, 46, 589-604.	1.8	8
425	Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease Associated With Cancer. Evidence and Recommendations. Angiologia, 2021, .	0.1	1
426	Pulmonary Artery Thrombosis: Strategy of Anticoagulation. Khirurgiya, 2021, .	0.5	3
427	Methods of Venous Thromboembolic Prophylaxis in Orthopedic Surgeries. Benha Medical Journal, 2020, 37, 710-722.	0.1	0
428	Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method. Acta Scientific Pharmaceutical Sciences, 2020, 4, 145-175.	0.2	0
429	National Guidelines on the Management of Venous Thromboembolism: Joint Guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society. Turkish Journal of Thoracic and Cardiovascular Surgery, 2021, 29, 562-576.	0.5	3
430	Antithrombotic Therapy for Secondary Prevention of Unprovoked Venous Thromboembolism: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Annals of Medicine, 2022, 54, 253-261.	5.0	5
431	Pulmonary Embolism and Deep Vein Thrombosis. , 2022, .		0
432	Epigenetic Regulation of F2RL3 Associates With Myocardial Infarction and Platelet Function. Circulation Research, 2022, 130, 384-400.	15.7	34

#	Article	IF	Citations
433	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: A Position Paper From the ESC Working Group on Thrombosis, in Collaboration With the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	8.4	62
434	Practical Guidance for New Multiple Myeloma Treatment Regimens: A Nursing Perspective. Seminars in Oncology, 2022, 49, 103-117.	5.8	4
435	Low Dose Apixaban as Secondary Prophylaxis of Venous Thromboembolism in Cancer Patients – 30 Months Follow-Up. Journal of Thrombosis and Haemostasis, 2022, 20, 1166-1181.	5.0	44
436	Noninvasive Vascular Diagnosis. , 2022, .		12
437	Comparative Efficacy and Safety of Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Patients With Different Renal Functions: A Systematic Review, Pairwise and Network Meta-Analysis. BMJ Open, 2022, 12, e048619.	2.7	13
438	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. Thrombosis and Haemostasis, 2022, 122, 1279-1287.	4.6	17
439	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 1051-1060.	37.0	33
440	Comparing Direct Oral Anticoagulants and Vitamin K Antagonist Use in Morbidly Obese Patients With Venous Thromboembolism: A Single Center Retrospective Cohort Study. EJHaem, 2022, 3, 457-462.	1.5	5
441	Clinical Implication of the Right Ventricular/Left Ventricular Diameter Ratio in Patients With Pulmonary Thromboembolism Subanalysis From the J'xactly Study. International Heart Journal, 2022, 63, 255-263.	1.4	3
442	Both G Protein–Coupled and Immunoreceptor Tyrosine-Based Activation Motif Receptors Mediate Venous Thrombosis in Mice. Blood, 2022, 139, 3194-3203.	10.6	31
443	Non-Vitamin K Antagonist Oral Anticoagulants in Venous Thromboembolism Patients: A Meta-Analysis of Real-World Studies. BMC Cardiovascular Disorders, 2022, 22, 1-10.	3.3	9
444	Prophylactic Anticoagulants for Non-Hospitalised People With COVID-19. Cochrane Database of Systematic Reviews, 2022, .	6.9	4
445	Women's Representation in Venous Thromboembolism Randomized Trials and Registries: The Illustrative Example of Direct Oral Anticoagulants for Acute Treatment. Contemporary Clinical Trials, 2022, 115, 106714.	2.1	9
446	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Current Oncology, 2021, 28, 5434-5451.	3.9	50
447	Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 775564.	3.2	6
448	Non-Synonymous Alterations in AKR7A3 and ABCA6 Correlate With Bleeding in Aged Patients Treated With Rivaroxaban. Clinical and Translational Science, 2022, 15, 923-929.	4.1	13
449	Pulmonary Thromboembolism and COVID-19: Place for Anticoagulant Therapy. , 2020, .		1
450	Некоторые аспекты применения антикоагулянтов при венозных тромбоэмболиях, тромбоэмболии легочной артерии. Фокус на пожилых пациентов. Russian Journal of Cardiology, 2022, 27, 4944.	1.9	1

#	Article	IF	Citations
451	Update: Antikoagulationstherapie Bei Tumorassoziierter Venöser Thromboembolie. Aktuelle Kardiologie, 2022, 11, 131-135.	0.0	1
452	Rivaroxaban in the Treatment of TEK-Related Venous Malformation. Australasian Journal of Dermatology, 2022, 63, e255-e258.	1.3	8
453	Design and Rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) Study. BMJ Open, 2018, 8, e020286.	2.7	15
454	Effectiveness and Safety of Lower Dose of Rivaroxaban for Cancer-Related Venous Thromboembolism: A Retrospective Cohort Study. Annals of Pharmacotherapy, 2022, 56, 1308-1314.	2.9	0
455	Direct Oral Anticoagulant Drugs in the Treatment of Pulmonary Thromboembolism. Galenika Medical Journal, 2022, 1, 15-21.	0.1	0
456	Extended Anticoagulation in Cancer-Associated Thrombosis (CAT): Can We Lower the Dose Yet?. The Hematologist, 2022, .	0.2	0
457	Response-Adaptive Treatment Randomization for Multiple Comparisons of Treatments With Recurrent Event Responses. Statistical Methods in Medical Research, 2022, 31, 1549-1565.	2.6	5
458	Beinvenenthrombose und Lungenembolie. Der Internist, 2022, 63, 601-611.	0.7	3
459	Characteristics and Clinical Outcomes of Japanese Patients With Venous Thromboembolism Receiving Under-Dose Rivaroxaban: Subanalysis of J'xactly. Current Medical Research and Opinion, 2022, 38, 1059-1068.	2.9	7
460	Management of Patients With Embolic Stroke of Unknown Source: Interpreting the Evidence in the Light of Clinical Judgement. Current Neurology and Neuroscience Reports, 2022, 22, 389-393.	8.7	5
461	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization. Journal of the American Heart Association, 2022, 11, e025342.	5.8	6
462	Extended Anticoagulation for Venous Thromboembolism: A Survey of the American Venous Forum and the European Venous Forum. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 1012-1020.e3.	2.6	3
463	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiology, 2022, 7, 747-759.	16.3	52
464	Are Outpatient Anticoagulation Management Services the Wave of the Future (Again)?. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12735.	3.3	3
465	Physician Perceptions and Use of Reduced-Dose Direct Oral Anticoagulants for Extended Phase Venous Thromboembolism Treatment. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12740.	3.3	4
466	Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis. Journal of the American Heart Association, 2022, 11, e024425.	5.8	19
467	Cancer-Associated Venous Thromboembolism: Incidence and Features in a Racially Diverse Population. Journal of Thrombosis and Haemostasis, 2022, 20, 2366-2378.	5.0	18
468	Risk Factors for Recurrent Venous Thromboembolism: A Real-World Analysis. Blood Coagulation and Fibrinolysis, 2022, 33, 301.	1.0	9

#	Article	IF	Citations
469	Diagnosis and Management of Pulmonary Embolism. Emergency Medicine Clinics of North America, 2022, 40, 565-581.	1.8	33
470	Direct Oral Anticoagulants After Bariatric Surgery—What Is the Evidence?. Journal of Thrombosis and Haemostasis, 2022, 20, 1988-2000.	5.0	43
471	Antiplatelet Agents for the Treatment of Deep Venous Thrombosis. Cochrane Database of Systematic Reviews, 2022, 7, CD012369.	6.9	22
472	"Low Dose Apixaban as Secondary Prophylaxis of Venous Thromboembolism in Cancer Patients—30 Months Follow-Up": Comment From Serrao et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 1935-1937.	5.0	3
473	Efficacy and Safety of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: Protocol for a Multicentre, Randomised, Warfarin-Controlled, Parallel Group Trial - KABUKI Trial. BMJ Open, 2022, 12, e061225.	2.7	5
474	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thrombosis and Haemostasis, 2022, 122, 1625-1652.	4.6	110
475	Pulmonary Embolism. New England Journal of Medicine, 2022, 387, 45-57.	76.6	174
476	Overall Haemostatic Potential (OHP) Assay Can Risk Stratify for Venous Thromboembolism Recurrence in Anticoagulated Patients. Journal of Thrombosis and Thrombolysis, 2023, 55, 32-41.	2.2	8
477	D-Dimer and Reduced-Dose Apixaban for Extended Treatment After Unprovoked Venous Thromboembolism: The Apidulcis Study. Blood Advances, 2022, 6, 6005-6015.	6.3	26
478	Les thromboses veineuses sous traitement anticoagulant : mise au point diagnostique, étiologique et thérapeutique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2022, 2022, 11-15.	0.0	0
479	How Would You Treat This Patient With Pulmonary Embolism?. Annals of Internal Medicine, 2022, 175, 1161-1169.	12.9	1
480	Challenging Clinical Scenarios for Therapeutic Anticoagulation: A Practical Approach. Thrombosis Research, 2022, 218, 72-82.	2.9	14
481	Outcome of Anticoagulation With Rivaroxaban in Patients With Non-Retrieved Inferior Vena Cava Filters for the Prevention of Filter Thrombosis: A Retrospective Cohort Study. BMC Cardiovascular Disorders, 2022, 22, 1-8.	3.3	6
482	Anticoagulant for Treatment and Prophylaxis of Venous Thromboembolism Patients With Renal Dysfunction: A Systematic Review and Network Meta-Analysis. Frontiers in Medicine, 2022, 9, 979911.	3.7	4
483	Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients With Acute Pulmonary Embolism—From Modern Recommendations to Clinical Application. Pharmaceuticals, 2022, 15, 1146.	6.1	4
484	Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients With Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data From the MAC Project. Life, 2022, 12, 1657.	4.3	9
485	Risk and Management of Bleeding Complications With Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Venous Thromboembolism: A Narrative Review. Advances in Therapy, 2023, 40, 41-66.	5.0	121
486	Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients With Cancer and Venous Thromboembolism: A Preliminary Data Analysis From the Mac Project. Life, 2022, 12, 1725.	4.3	2

#	Article	IF	Citations
487	Subgroup Analyses in Venous Thromboembolism Trials Reporting Pharmacological Interventions: A Systematic Review. Thrombosis Research, 2023, 232, 151-159.	2.9	1
488	Platelets and Their Role in Hemostasis and Thrombosis—From Physiology to Pathophysiology and Therapeutic Implications. International Journal of Molecular Sciences, 2022, 23, 12772.	5.9	291
489	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. Vascular Health and Risk Management, 2022, 18, 793-807.	3.7	8
490	Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation. Journal of Clinical Medicine, 2022, 11, 5970.	3.8	26
491	"Guiding Lights" for the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension in the Flow of Patients With Pulmonary Embolism. Terapevticheskii Arkhiv, 2022, 94, 1052-1056.	0.9	3
492	Transgender Medicine and Risk of Venous Thromboembolism. Hamostaseologie, 2022, 42, 301-307.	1.5	8
493	Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. Journal of the American College of Cardiology, 2023, 81, 16-30.	12.0	173
494	Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases. International Journal of Molecular Sciences, 2022, 23, 13176.	5.9	58
495	Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real-World Practice Mirrors Guideline Recommendations. Journal of the American Heart Association, 2022, 11, e025471.	5.8	10
496	Platelet in Thrombo-Inflammation: Unraveling New Therapeutic Targets. Frontiers in Immunology, 2022, 13, 1039843.	6.9	85
497	A Commitment to Global Collaboration, Welcoming International Participation and Advancing Science for the Benefit of Patients. Bleeding, Thrombosis, and Vascular Biology, 2022, .	0.3	0
498	Non-Vitamin K Antagonist Oral Anticoagulants for COVID-19 Thrombosis. Journal of Acute Disease, 2022, 11, 212-221.	0.5	0
499	Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis. NEJM Evidence, 2022, 1, EVIDoa2200104.	10.7	61
500	Clinical and Safety Outcomes Associated With Extended Treatment of Venous Thromboembolism: A Network Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 414.	2.9	5
501	Protocolo de anticoagulación en la tromboembolia pulmonar. Medicine, 2022, 13, 4032-4035.	0.1	0
502	Update zum Thema Lungenembolie: leitliniengerechte Diagnostik und Therapie anhand eines Fallbeispiels. Praxis, 2022, 111, 939-946.	0.3	1
503	Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review. Endocrine Practice, 2023, 29, 272-278.	3.9	45
504	Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs. Cancers, 2023, 15, 11.	5.3	26

#	Article	IF	Citations
505	Protocol for a Modelling Study to Assess the Clinical and Cost-Effectiveness of Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. BMJ Open, 2023, 13, e053927.	2.7	2
506	Clinical Studies With Anticoagulants That Have Changed Clinical Practice. Seminars in Thrombosis and Hemostasis, 2023, 49, 242-254.	4.1	9
507	Recurrent Venous Thromboembolism and Bleeding With Extended Anticoagulation: The VTE-PREDICT Risk Score. European Heart Journal, 2023, 44, 1231-1244.	14.7	84
508	Walking the Tightrope: A Balanced Discussion of the Benefits and Harms of Extended Duration Anticoagulation for Venous Thrombo-Embolism. European Heart Journal, 2023, 44, 1245-1247.	14.7	6
509	Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis After a Fracture. New England Journal of Medicine, 2023, 388, 203-213.	76.6	159
510	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Pulmonary Embolism. Cochrane Database of Systematic Reviews, 2023, 4, CD010957.	6.9	12
511	PERT Consortium Handbook of Pulmonary Embolism. , 2023, .		7
512	Residual Pulmonary Vascular Obstruction and Recurrence After Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis of Individual Participant Data. Journal of Thrombosis and Haemostasis, 2023, 21, 1519-1528.e2.	5.0	26
513	Direct Oral Anticoagulants in Obese Patients With Venous Thromboembolism: Results of an Expert Consensus Panel. American Journal of Medicine, 2023, 136, 523-533.	3.2	29
514	Major Acute Cardiovascular Events After Venous Thromboembolism: A Meta-Analysis of Randomized Trials. Journal of Thrombosis and Haemostasis, 2023, 21, 1674-1676.	5.0	4
515	An Update in Anticoagulant Therapy for Patients With Cancer-Associated Venous Thromboembolism. Current Oncology Reports, 2023, 25, 425-432.	5.8	5
516	Long-Term Outcome of Chronic Thromboembolic Pulmonary Hypertension Using Direct Oral Anticoagulants and Warfarin: A Japanese Prospective Cohort Study. Journal of Thrombosis and Haemostasis, 2023, 21, 2151-2162.	5.0	28
517	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Deep Vein Thrombosis. Cochrane Database of Systematic Reviews, 2023, 4, CD010956.	6.9	27
518	Extension Treatment: Preventing Recurrence of Venous Thromboembolism. European Medical Journal Hematology, 2023, .	0.0	0
519	Traitement anticoagulant de la maladie thromboembolique veineuse à la phase chronique. La Presse Médicale Formation, 2023, 4, 181-188.	0.1	0
520	Pharmacokinetic Drug–Drug Interactions With Direct Anticoagulants in the Management of Cancer-Associated Thrombosis. British Journal of Clinical Pharmacology, 2023, 89, 2369-2376.	3.0	15
521	Oral Anticoagulation Therapy in the Treatment of Pulmonary Thromboembolism. Galenika Medical Journal, 2023, 2, 62-66.	0.1	0
522	Geriatrische Nephrologie. , 2023, .		6

#	Article	IF	Citations
523	Rivaroxaban in Patients With Abdominal Aortic Aneurysm and High-Sensitivity C-Reactive Protein Elevation (BANBOO): Study Protocol for a Randomized, Controlled Trial. Trials, 2023, 24, 1-10.	2.6	2
524	SOP Lungenarterienembolie. Notfallmedizin Up2date, 2023, 18, 123-126.	0.2	0
525	Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American Journal of Cardiovascular Drugs, 2023, 23, 247-255.	3.7	6
526	Prevalence and Predictors of Inappropriate Antithrombotic Prescription in Patients Presenting With Traumatic Brain Injury. Neurosurgery, 2023, 93, 1019.	3.6	2
527	Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2023, 176, 949-960.	12.9	14
528	Unprovoked Venous Thromboembolism: The Search for the Cause. Medical Clinics of North America, 2023, 107, 861-882.	5.3	3
529	Anticoagulant Use in Older Persons at Risk for Falls: Therapeutic Dilemmas—A Clinical Review. European Geriatric Medicine, 2023, 14, 683-696.	3.9	37
530	Management of Thromboembolic Disease in Patients With Primary and Metastatic Brain Tumors. Current Treatment Options in Oncology, 2023, 24, 1293-1303.	6.1	4
531	Acute Deep Vein Thrombosis. , 2023, .		0
532	Endothelial Dysfunction, Platelet Hyperactivity, Hypertension, and the Metabolic Syndrome: Molecular Insights and Combating Strategies. Frontiers in Nutrition, 2023, 10, 1221438.	5.6	95
533	Prophylactic Anticoagulants for Non-Hospitalised People With COVID-19. Cochrane Database of Systematic Reviews, 2023, 8, CD015102.	6.9	13
534	The Risk of Recurrent Venous Thromboembolism After Discontinuation of Anticoagulant Therapy in Patients With Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. EClinicalMedicine, 2023, 64, 102194.	13.5	44
535	Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus. Flebologiya, 2023, 17, 152-296.	1.4	76
536	Antithrombotic Secondary Prophylaxis With Low Dose of Apixaban or Rivaroxaban in the Onco-Hematologic Patients: Comparison With Non-Neoplastic Patients. Annals of Hematology, 2023, 102, 2599-2605.	2.1	5
537	Direct Oral Anticoagulants for Inferior Vena Cava Agenesis. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 10760296231200224.	2.2	7
538	Limb Preservation for the Vascular Specialist. , 2023, .		2
539	Hemostatic Considerations for Gender Affirming Care. Thrombosis Research, 2023, 230, 126-132.	2.9	6
540	A Prognostic Score to Identify Women at Increased Risk for Abnormal Uterine Bleeding During Anticoagulation for Venous Thromboembolism. Thrombosis Update, 2023, 13, 100148.	1.6	3

#	Article	IF	Citations
541	Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience With a Focus on Female Patients. Journal of Clinical Medicine, 2023, 12, 6427.	3.8	3
542	Intensify Standardized Anticoagulation for Cancer-Associated Pulmonary Embolism: From Single-Center Real-World Data. Clinical Therapeutics, 2023, 45, 1236-1243.	3.4	3
543	Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling. Annals of Biomedical Engineering, 2024, 52, 1-20.	5.5	38
544	Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients With Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study. Advances in Therapy, 2024, 41, 1-22.	5.0	7
545	Provoked vs Minimally Provoked vs Unprovoked VTE: Does It Matter?. Hematology, 2023, 2023, 600-605.	2.5	8
546	Venous Thromboembolism Prophylaxis and Multiple Myeloma Patients in Real-Life: Results of a Large Survey and Clinical Guidance Recommendations From the IFM Group. Thrombosis Research, 2024, 233, 153-164.	2.9	25
547	Effects of Antiplatelet Therapy on Menstrual Blood Loss in Reproductive-Aged Women: A Systematic Review. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102295.	3.3	4
548	Primary Care Clinicians' Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment. Journal of Clinical Medicine, 2024, 13, 96.	3.8	2
549	Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis. Journal of Clinical Oncology, 2024, 42, 494-499.	23.9	4
550	Choice and Duration of Anticoagulation for Venous Thromboembolism. Journal of Clinical Medicine, 2024, 13, 301.	3.8	17
551	Direct-Acting Oral Anticoagulants in Patients at Extremes of Body Weight: A Review of Pharmacological Considerations and Clinical Implications. TH Open, 2024, 08, e31-e41.	1.8	16
552	THromboprophylaxis in Sickle Cell Disease With Central Venous Catheters (THIS): An Internal Pilot Randomised Controlled Trial Protocol. BMJ Open, 2024, 14, e079363.	2.7	4
553	When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2024, 83, 444-465.	12.0	87
554	Antiplatelet Period Drama: A Rush of Blood or Classic Crimson Tide?. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102320.	3.3	0
555	Extracellular Vesicles From Activated Platelets Possess a Phospholipid-Rich Biomolecular Profile and Enhance Prothrombinase Activity. Journal of Thrombosis and Haemostasis, 2024, 22, 1463-1474.	5.0	27
556	Massive Pulmonary Embolism Related to a Patient With Heart Failure Secondary to Stress Cardiomyopathy: A Case Report. Cureus, 2024, 16, e52985.	1.3	0
557	Unapproved Dose of Direct Oral Anticoagulants for Venous Thromboembolism — Right or Wrong? —. Circulation Journal, 2024, 88, CJ-24-0063.	4.0	1
558	Efficacy and Safety of Anticoagulant for Treatment and Prophylaxis of VTE Patients With Renal Insufficiency: A Systemic Review and Meta-Analysis. Thrombosis Journal, 2024, 22, 1-11.	2.9	7

#	Article	IF	Citations
559	How I Treat the Co-Occurrence of Venous and Arterial Thromboembolism: Anticoagulation, Antiplatelet Therapy, or Both?. Blood, 2024, 143, 2351-2362.	10.6	17
560	The Effect of Off-Label Use of Reduced-Dose Direct Oral Anticoagulants Therapy in the Treatment of Pulmonary Embolism Comparable to Standard-Dose Therapy. Heart and Vessels, 2024, 39, 365-372.	1.8	1
561	Long-Term Outcomes in Two-Year Follow-Up After Primary Treatment in Patients With a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study. Journal of Clinical Medicine, 2024, 13, 1343.	3.8	3
562	Secondary Prophylaxis of Venous Thromboembolism (VTE) With Low Dose Apixaban or Rivaroxaban: Results From a Patient Population With More Than 2 Years of Median Follow-Up. Mediterranean Journal of Hematology and Infectious Diseases, 2024, 16, e2024020.	1.7	6
563	Venöse Thromboembolie – was ist neu in der aktualisierten AWMF-Leitlinie?. Deutsche Medizinische Wochenschrift, 2024, 149, 274-282.	0.3	4
564	Direct Oral Anticoagulants for Pulmonary Embolism. Hamostaseologie, 2024, 44, 206-217.	1.5	7
565	Analysis of Sex Hormones, Insulin Dosage, and Risk Factors Associated With Male Diabetic Patients. American Journal of Men's Health, 2024, 18, 15579883241235062.	2.5	4
566	Рецидивирующее течение тромбоэмболии легочной артерии и острый инфаркт миокарда без подъема сегмента ST: актуальные проблемы диагностики и лечения (клинический случай). Sibirskij žurnal Kliničeskoj I èksperimental'noj Mediciny, 2024, 39, 194-201.	0.5	1
567	Cancer-Associated Thrombosis in Vietnam: Literature Review and Expert Perspectives. Journal of Applied Hematology, 2024, 15, 9.	0.4	1
568	Anticoagulation in the Management of Acute Pulmonary Embolism—A Review. International Journal of Angiology, 2024, 33, 095-100.	1.1	1
569	Long-Term Efficacy and Safety of Direct Oral Anticoagulants at Reduced Doses in the Secondary Prevention of Venous Thromboembolism and Post-Thrombotic Syndrome. Journal of Clinical Medicine, 2024, 13, 2394.	3.8	7
570	Edoxaban for 12 vs. 3 Months in Cancer-Associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights From the ONCO DVT Study. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 422-431.	5.0	9
571	VTEDOAC. The Japanese Journal of Phlebology, 2024, 35, 53-58.	0.3	0
572	Direct Oral Anticoagulants for Treatment of Venous Thrombosis: Illustrated Review of Appropriate Use. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102424.	3.3	7
573	Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline. Hamostaseologie, 2024, 44, 097-110.	1.5	21
574	A Systematic Review and Meta-Analysis of the Morbidity of Efficacy Endpoints and Bleeding Events in Elderly and Young Patients Treated With the Same Dose Rivaroxaban. Annals of Hematology, 2024, 103, 1-11.	2.1	3
575	Anticoagulation Management Post Pulmonary Embolism. Methodist DeBakey Cardiovascular Journal, 2024, 20, 27-35.	1.8	4
576	Risk of Recurrent Venous Thromboembolism and Major Bleeding According to Risk Factor Profiles in Asian Patients: A Subgroup Analysis EINSTEIN-Extension and EINSTEIN-CHOICE. Thrombosis Journal, 2024, 22, 1-6.	2.9	0

#	Article	IF	Citations
577	Длительная антикоагулянтная терапия в аспекте вторичной профилактики рецидива тромбоэмболии легочной артерии. Cardiovascular Therapy and Prevention (Russian Federation), 2024, 23, 3869.	1.4	1
578	Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2024, 8, 321-328.	5.4	3
579	Efficacy and Safety of Rivaroxaban for Extremely Aged Patients With Venous Thromboembolism: A Retrospective, Cross-Sectional Real-World Study. Clinical Interventions in Aging, 2024, 19, 1103-1116.	4.2	2
580	Rivaroxaban's Vascular Dose for the Neurovascular Clinician. Chinese Neurosurgical Journal, 2024, 10, 1-3.	1.5	0
581	Optimal Long-Term Anticoagulation After Acute Pulmonary Embolism: Current State of the Art and a Look Into the Near Future. Current Opinion in Pulmonary Medicine, 2024, 30, 10.1097/MCP.0000000000001106.	2.8	0
582	Poor Patients' Knowledge About Venous Thromboembolism and Its Therapy Is Associated With Increased Risk of Major Bleeding and Discontinuation of Anticoagulation: A Cohort Study. Medicine (United States), 2024, 103, e38697.	2.1	2
583	Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis. Annals of Vascular Surgery, 2024, 0, 508-518.	1.8	2
584	Anticoagulant Therapy in Renal Insufficiency Theme: Anticoagulation in Complex Situations. Thrombosis Research, 2024, 241, 109097.	2.9	3
585	Anticoagulation and Compression Therapy for Proximal Acute Deep Vein Thrombosis. Vasa - European Journal of Vascular Medicine, 2024, 53, 289-297.	2.7	9
586	Treating Cancer-Associated Venous Thromboembolism: A Practical Approach. European Journal of Cancer, 2024, 209, 114263.	6.7	22
587	The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study From a Tertiary Referral Centre. Thrombosis and Haemostasis, 2025, 0, 379-384.	4.6	11
588	Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review. Reviews in Cardiovascular Medicine, 2024, 25, 281.	2.5	22
589	Duration of Anticoagulation of Venous Thromboembolism. Presse Medicale, 2024, 53, 104245.	4.8	1
590	Sonothrombolysis Using Microfluidically Produced Microbubbles in a Murine Model of Deep Vein Thrombosis. Annals of Biomedical Engineering, 2025, 53, 1-11.	5.5	1
591	Lungenembolie: ambulante Therapie und Nachsorge. Deutsche Medizinische Wochenschrift, 2024, 149, 1191-1199.	0.3	0
592	Secondary Prophylaxis of Venous Thromboembolism (VTE) With Low Dose Apixaban or Rivaroxaban in Major-Thrombophilia Carriers. Annals of Hematology, 2024, 103, 1-9.	2.1	4
593	Guidelines on Deep Vein Thrombosis of the Brazilian Society of Angiology and Vascular Surgery. Jornal Vascular Brasileiro, 2024, 23, e20230107.	1.0	10
594	Long-Term Monitoring and Treatment of Venous Thromboembolic Disease: Recommendations of the Thromboembolic Disease Group of the Spanish Society of Internal Medicine 2024. Revista Clínica Española, 2024, 224, 652-663.	1.1	0

#	Article	IF	Citations
595	Venous Thromboembolism Secondary Prophylaxis in Elderly People (Over 75-Year-Old) With Low-Dose Direct Oral Anticoagulants: Single-Center Italian Experience. Blood Coagulation and Fibrinolysis, 2024, 35, 349.	1.0	3
596	Venous Thromboembolism After Hospital Discharge: Temporal Trends in Baseline Characteristics, Prevention, Treatment, and 90-Day Outcomes. Seminars in Thrombosis and Hemostasis, 2025, 51, 301-311.	4.1	3
597	Changes in the Landscape of Anticoagulation: A Focus on Direct Oral Anticoagulants. Lancet Haematology,the, 2024, 11, e938-e950.	14.9	43
598	Seguimiento y tratamiento de la enfermedad tromboembólica venosa a largo plazo: recomendaciones del Grupo de Enfermedad Tromboembólica de la Sociedad Española de Medicina Interna 2024. Revista Clinica Espanola, 2024, 224, 652-663.	0.3	4
599	Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology – 2024. Arquivos Brasileiros De Cardiologia, 2024, .	1.2	16
600	Off-Label Dosing of Direct Oral Anticoagulants: Prescribing Error or Opportunity in Treating Patients With Atrial Fibrillation?. Thrombosis and Haemostasis, 2025, 125, 286-289.	4.6	1
601	Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid. Thrombosis and Haemostasis, 2025, 125, 611-617.	4.6	11
602	Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation, 2025, 151, 589-600.	24.6	27
603	Reduced- Versus Full-Dose Anticoagulants for the Extended Treatment of Cancer-Associated Venous Thromboembolism in Thai Patients. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102643.	3.3	6
604	Venous Thromboembolism. Learning Materials in Biosciences, 2024, .	0.0	0
605	Risk of Intracranial Hemorrhage Associated With Direct Oral Anticoagulation vs Antiplatelet Therapy: A Systematic Review and Meta-Analysis. JAMA Network Open, 2024, 7, e2449017-e2449017.	10.2	33
606	Direct Oral Anticoagulants in Deep Vein Thrombosis Associated With Inferior Vena Cava Agenesis: A Report of Three Cases and a Systematic Review. IJC Heart and Vasculature, 2025, 56, 101565.	2.6	2
607	Hormone-Related Thrombosis: Duration of Anticoagulation, Risk of Recurrence, and the Role of Hypercoagulability Testing. Hematology, 2024, 2024, 664-671.	2.5	6
608	Gender-Affirming Hormone Therapy in the Transgender Patient: Influence on Thrombotic Risk. Hematology, 2024, 2024, 652-663.	2.5	15
609	Anticoagulants: From Chance Discovery to Structure-Based Design. Pharmacological Reviews, 2025, 77, 100037.	18.6	5
610	No Title. , 0, .		0
611	No Title. , 0, .		0
612	No Title. , 0, .		0

#	Article	IF	Citations
613	No Title. , 0, .		0
614	No Title. , 0, .		0
615	Bleeding Risks With Non–Vitamin K Oral Anticoagulants Versus Single Antiplatelet Therapy. Annals of Internal Medicine, 2025, 178, 360-368.	12.9	7
616	Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism. JACC Basic To Translational Science, 2025, 10, 689-703.	4.6	13
617	Anticoagulation for Extended Venous Thromboembolism Treatment: Less Is Really More. Lancet, The, 2025, 405, 676-677.	96.9	0
618	Extended Treatment of Venous Thromboembolism With Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence: A Non-Inferiority, Multicentre, Randomised, Open-Label, Blinded Endpoint Trial. Lancet, The, 2025, 405, 725-735.	96.9	111
619	Milestones in Therapeutic and Antithrombotic Strategies for Chronic Thromboembolic Pulmonary Hypertension. Journal of Cardiology, 2025, 86, 127-133.	3.8	6
620	A Saudi Heart Association Position Statement on the Use of DOACs in Patients With Arterial and Venous Thrombosis. Journal of the Saudi Heart Association, 2025, 37, 2.	1.5	0
621	Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism. Drugs and Aging, 2025, 42, 469-484.	4.9	3
622	Direct Oral Anticoagulant Failure in Patients With Venous Thromboembolism—Why and What Next?. Journal of Thrombosis and Haemostasis, 2025, 23, 1774-1786.	5.0	6
623	Anticoagulation Therapy for Venous Thromboembolism. Medical Clinics of North America, 2025, 109, 803-826.	5.3	0
624	Extended-Phase Anticoagulant Treatment of Acute Venous Thromboembolism in Children: A Cohort Study From the EINSTEIN-Jr Phase 3 Trial. Lancet Haematology,the, 2025, 12, e357-e364.	14.9	9
625	Risk Factors and Management of Cancer-Associated Thrombosis: The Ongoing Battle Between Efficacy and Safety of Anticoagulation. Medical Clinics of North America, 2025, 109, 857-873.	5.3	3
626	The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches. Current Issues in Molecular Biology, 2025, 47, 291.	4.3	12
627	Residual Pulmonary Vascular Obstruction Computed With Ventilation/Perfusion Single Photon Emission Computed Tomography/Computed Tomography to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism: Protocol for a Cohort Study (PRONOSPECT). Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102867.	3.3	1
628	Lessons From EINSTEIN-Jr and Next Steps for Extended-Phase Anticoagulation in Paediatric Venous Thromboembolism. Lancet Haematology,the, 2025, 12, e321-e323.	14.9	0
629	The Current Status and Future Perspective of Extended Anticoagulation Therapy for Cancer-Associated Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2025, 58, 601-607.	2.2	3
630	Evaluation of Extended Direct Oral Anticoagulant Dosing Strategies in Patients With and Without Cancer From a Prospective Observational Registry. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102878.	3.3	5

#	Article	IF	Citations
631	Prescribing Preferences for Reduced-Dose Direct Oral Anticoagulation for Extended-Phase Venous Thromboembolism Treatment. Thrombosis Research, 2025, 250, 109338.	2.9	0
632	The Critical Role of Platelets in Venous Thromboembolism: Pathogenesis, Clinical Status, and Emerging Therapeutic Strategies. Blood Reviews, 2025, 74, 101302.	7.6	19
633	Brazilian Guidelines for the Pharmacological Treatment of Pulmonary Embolism. Official Document of the Brazilian Thoracic Association Based on the GRADE Methodology. Jornal Brasileiro De Pneumologia, 2025, 51, e20240314.	1.4	1
634	The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?. Diagnostics, 2025, 15, 1348.	4.9	1
635	Oral Anticoagulants in Women: What's the Difference? A Narrative Review. Clinical and Applied Thrombosis/Hemostasis, 2025, 31, 10760296251347938.	2.2	2
636	2025 Guidelines for Direct Oral Anticoagulants: A Practical Guidance on the Prescription, Laboratory Testing, Peri-Operative and Bleeding Management. Internal Medicine Journal, 2025, 55, 1174-1183.	1.6	34
637	In VTE at High Risk for Recurrence, Reduced- vs. Full-Dose DOACs Did Not Differ for Symptomatic Recurrence but Reduced Bleeding at 37 Mo. Annals of Internal Medicine, 2025, 178, JC63.	12.9	0
638	Menstrual Bleeding-Specific Quality of Life in Women on Antiplatelet Therapy. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102910.	3.3	0
639	New Horizons in the Pharmacological Management of Venous Thromboembolism. HemaSphere, 2025, 9, e70143.	3.9	2
640	Terapias anticoagulantes 86 años después. Viejas y nuevas drogas. Viejos y nuevos errores. Revista Hematología, 2025, 29, 28-41.	0.1	0
641	Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thrombosis and Haemostasis, 2025, 125, 1085-1098.	4.6	4
642	Thrombosis and Thrombophilia. , 2022, .		0
643	Efficacy and Safety of Direct Oral Anticoagulants in Patients With Venous Thrombosis and Inherited Thrombophilia. International Journal of Medical Sciences, 2025, 22, 3182-3190.	3.8	1
644	Less Is More: Low-Dose Direct Oral Anticoagulants for Extended Venous Thromboembolism Prophylaxis in Higher-Risk Patients. The Hematologist, 2025, .	0.2	2
645	Enfermedad venosa Aguda. Medicine, 2025, 14, 2192-2200.	0.1	1
646	Introduction to Venous Thromboembolism and Antithrombotic Drugs. , 2025, .		0
647	NOACs for VTE Prevention in Patients With Lower Limb Fracture: A Systematic Review and Meta-Analysis. Journal of Orthopaedic Surgery and Research, 2025, 20, 659.	4.0	3
648	Efficacy and Safety of Anticoagulant Treatment in Elderly Patients With Venous Thromboembolism Beyond the First 3 to 6 Months of Therapy: A Narrative Review. Thrombosis Research, 2025, 253, 109403.	2.9	4

#	Article	IF	Citations
649	Extended Reduced Versus Full-Dose Treatment With Factor Xa Inhibitors in Patients With Venous Thromboembolism: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026, 399, 1-13.	4.7	5
650	The History and Historical Treatments of Deep Vein Thrombosis: Toward the Era of New Anticoagulants. Journal of Thrombosis and Haemostasis, 2025, 23, 3654-3664.	5.0	3
651	Long-Term Antithrombotic Therapy Practices in Adult Patients With Short Bowel Syndrome Following Acute Mesenteric Ischemia: An International Case-Based Survey. Clinical Nutrition ESPEN, 2025, 69, 421-427.	3.2	3
652	Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Meta-Analysis of Randomized Controlled Trials. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102996.	3.3	3
653	Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-Associated Venous Thromboembolism: Guidance From an Expert Panel. Hamostaseologie, 2025, .	1.5	3
654	Reduced Dose Versus Full Dose of Direct Oral Anticoagulation in Extended Treatment of Venous Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Haemostasis, 2025, 23, 3733-3737.	5.0	1
655	Low-Dose Direct Oral Anticoagulants for Secondary Prevention in Patients at High Risk for Recurrence Due to History of Recurrent Venous Thromboembolic Events or Severe Thrombophilia: A Retrospective Analysis of the Italian Survey on anTicoagulated pAtients RegisTry 2. Journal of Thrombosis and Haemostasis, 2025, 23, 3625-3632.	5.0	5
656	Retrospective Observational Study on Diagnosis and Treatment Trends of DVT in Japan: Japanese Vein Study XXVI. Annals of Vascular Diseases, 2025, 18, oa.25-00061.	0.7	0
657	When Viral Myocarditis Meets Thrombosis Tendency: Deep Analysis of a Complex Case Report. Frontiers in Cardiovascular Medicine, 2025, 12, 1641074.	3.2	0
658	Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2026, 40, 1-9.	4.1	4
659	Residual Vein Thrombosis After Deep Vein Thrombosis in Patients Treated With DOACs: Incidence and Associated Factors. Journal of Clinical Medicine, 2025, 14, 5991.	3.8	1
660	Long-Term Efficacy and Safety of Direct Oral Anticoagulants in Venous Thrombotic Antiphospholipid Syndrome Patients Not Candidate to Warfarin: A Pilot Prospective Case Series Study. Journal of Thrombosis and Thrombolysis, 2026, 59, 1-8.	2.2	0
661	Efficacy and Safety of Reduced-Dose Versus Full-Dose DOACs in Extended Treatment of VTE: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Thrombolysis, 2026, 59, 1-9.	2.2	4
662	Apixaban for Extended Treatment of Provoked Venous Thromboembolism. New England Journal of Medicine, 2025, 393, 1166-1176.	76.6	55
663	Тромбообразование при воспалительных заболеваниях кишечника: роль факторов риска, маркеры, методы диагностики и направления будущих исследований. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2025, 0, 163-171.	0.4	0
664	The Efficacy of Different Treatment Strategies of Direct Oral Anticoagulants in Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis. , 2025, .		0
665	Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Baylor University Medical Center Proceedings, 2025, 38, 907-918.	1.0	3
666	Reduced-Dose Direct Oral Anticoagulants for the Secondary Prevention of Venous Thromboembolism: Finding the Sweet Spot. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103170.	3.3	0

#	Article	IF	Citations
667	Efficacy and Safety of Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Meta-Analysis With Trial Sequential Analysis and Reconstructed Time-to-Event Data. Thrombosis Research, 2025, 254, 109476.	2.9	5
668	From Algorithms to Biomarkers: Toward Personalized Management of Venous Thromboembolism. Journal of Clinical Medicine, 2025, 14, 6172.	3.8	0
669	Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study. Diagnostics, 2025, 15, 2283.	4.9	1
670	Practical Guide to Management After an Acute Pulmonary Embolism. BMJ Open Respiratory Research, 2025, 12, e003028.	3.8	2
671	Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials. American Journal of Hematology, 2025, 100, 2276-2285.	9.8	4
672	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	0
673	Long Term Anticoagulation for Catheter-Related Deep Vein Thrombosis of the Upper Extremities in Women With Cancer: Retrospective Analysis of Effectiveness and Safety Outcomes. Journal of Thrombosis and Thrombolysis, 2025, 58, 1-8.	2.2	4
674	Indefinite Anticoagulation With Reduced-Intensity Direct Oral Anticoagulants in Patients With Splanchnic Vein Thrombosis. An International Practice Survey. Blood Coagulation and Fibrinolysis, 2025, 36, 364.	1.0	3
675	Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets. Thrombosis and Haemostasis, 2026, 126, 930-947.	4.6	1
676	The Fibrinolytic System in Disease: From Molecular Pathways to Clinical Outcomes. Thrombosis Research, 2025, 256, 109504.	2.9	8
677	Platelets in Venous Thromboembolism. , 2025, .		0
678	Antiplatelet Therapy for Venous Thromboembolism. , 2025, .		0
679	Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis. Seminars in Thrombosis and Hemostasis, 2026, 52, 236-247.	4.1	3
680	Robotic-Assisted Simultaneous Bilateral Total Knee Arthroplasty in a Treated Case of Deep Vein Thrombosis. , 2025, 2, 75-81.		0
681	Weekly Journal Scan: Balancing Reduced Thromboembolic Recurrence With Enhanced Bleeding Liability Associated With Extended Low-Dose Anticoagulation. European Heart Journal, 2026, 47, 1128-1129.	14.7	0
682	Duration of Anticoagulation for Unprovoked Venous Thromboembolism. BMJ, The, 2025, 391, r2334.	11.6	1
683	Венозная тромбоэмболия. Что нас ждет впереди?. Malignant Tumours, 2025, 15, 60-65.	0.9	0
684	Full-Dose Versus Reduced-Dose Comparison of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2025, 16, 1708316.	5.3	1

#	Article	IF	Citations
685	Managing Patients With a History of Arterial Disease and New Venous Thromboembolism. Hematology, 2025, 2025, 22-33.	2.5	1
686	Anticoagulation in Malignancy: The Patient Who Bleeds and Clots Simultaneously. Hematology, 2025, 2025, 176-182.	2.5	1
687	A Tragedy Within a Tragedy: How the Inappropriate Request for D-Dimer During the COVID-19 Pandemic Might Have Harmed so Many People. Seminars in Thrombosis and Hemostasis, 2025, .	4.1	0
688	Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2025, 31, 10760296251408061.	2.2	1
689	Extended Treatment With Reduced-Dose Direct Oral Anticoagulants for Venous Thromboembolism: Systematic Review and Bayesian Noninferiority Reanalysis. Canadian Journal of Cardiology, 2026, 42, 1247-1257.	3.8	2
690	Reduced Versus Full-Dose Direct Oral Anticoagulants for Long-Term Management of Venous Thromboembolism: A Systematic Review. Journal of Clinical Medicine, 2026, 15, 770.	3.8	2
691	Reduced- Compared With Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis. TH Open, 2026, 10, a27980066.	1.8	0
692	Efficacy and Safety of Direct Oral Anticoagulants in Extended Venous Thromboembolism: A Placebo Controlled Grade Assessed Meta Analysis. Critical Pathways in Cardiology, 2026, 25, 10.1097/HPC.0000000000000417.	1.0	0
693	Venous Thromboembolism. , 2026, .		0
694	Not All Clots Are Created Equal: Refining Secondary Prevention of Venous Thromboembolism in Higher-Risk Patients. The Hematologist, 2026, .	0.2	0
695	Prescribing Patterns of Apixaban and Rivaroxaban for Extended-Phase Anticoagulant Therapy. American Journal of Health-System Pharmacy, 2026, 83, S3007-S3017.	1.4	0
696	Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism. International Journal of Molecular Sciences, 2026, 27, 1756.	5.9	1
697	Reduced-Dose DOACs for Secondary Prevention of Venous Thromboembolism: Interpreting the Latest Evidence. Internal Medicine Journal, 2026, 56, 729-730.	1.6	0
698	2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2026, 153, e977-e1051.	24.6	126
699	2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2026, 87, 1626-1710.	12.0	114
700	Reduced- Versus Extended-Dose Anticoagulation for Venous Thromboembolism in Patients With and Without Cancer: A Systematic Review and Meta-Analysis. European Journal of Haematology, 2026, 116, 863-872.	2.9	1
701	Scoping Review of Apixaban and Rivaroxaban Dosing for Atrial Fibrillation and Venous Thromboembolism in Advanced Chronic Kidney Disease. International Journal of Clinical Pharmacy, 2026, 48, 693-709.	3.6	0
702	Rate of Abnormal Uterine Bleeding in Women on Anticoagulation for Venous Thromboembolism: Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2026, 24, 1979-1992.	5.0	2

#	Article	IF	Citations
703	Extended Treatment for Venous Thromboembolism: Is Direct Oral Anticoagulant Dose-Reduction Better for All?. HemaSphere, 2026, 10, e70327.	3.9	0
704	Great Debates in Vascular Medicine: Interventional Therapy for Iliofemoral DVT and Anticoagulation Regimen After Iliac Stenting. Vascular Medicine, 2026, 31, 432-436.	2.3	0
705	Current Management of Cerebral Venous Thrombosis. Stroke, 2026, 57, 2228-2236.	9.1	1
706	Développement clinique de l'EP217609 et de son antidote l'avidine. , 0, .		0
707	Anticoagulation Therapy vs Clinical Surveillance in Isolated Subsegmental Pulmonary Embolism: A Systematic Review and Meta-Analysis. Thrombosis Research, 2026, 261, 109669.	2.9	4
708	Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the Society for Cardiovascular Angiography & Interventions, 2026, 5, 105317.	2.3	0
709	Management of Recurrent Venous Thromboembolism on Anticoagulation. Journal of Clinical Medicine, 2026, 15, 3415.	3.8	0
710	Efficacy and Safety of Low-Dose Versus Standard-Dose Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Baylor University Medical Center Proceedings, 2026, 39, 683-693.	1.0	1
711	Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use. Thrombosis and Haemostasis, 2026, 126, 1079-1083.	4.6	2
712	Thrombophilia Testing in Venous Thromboembolism: When, Who and Why It Matters. A Practical Review. Archives of Cardiovascular Diseases, 2026, 119, 604-614.	2.5	0
713	Rivaroxaban for Extended Anticoagulation of Pediatric Venous Thromboembolism. Translational Pediatrics, 2026, 15, 165.	1.9	0
714	Extended Anticoagulation in Provoked VTE With Persistent Risk Factors: A Meta-Analysis of Randomised Trials. Revista Romana De Cardiologie, 2026, 36, 170-177.	0.2	0
715	Subjective Theory of Illness, Disease Perception, and Attitude Toward Anticoagulation Therapy in Patients With Unprovoked Venous Thromboembolism-The Qualitative Dalí Study. Journal of Thrombosis and Haemostasis, 2026, 24, 3190-3200.	5.0	0
716	Robustness of Placebo-Controlled Trials of Extended-Duration Direct Oral Anticoagulant Therapy for Secondary Venous Thromboembolism Prevention. Internal and Emergency Medicine, 2026, 21, 2165-2174.	4.8	0
717	Emerging Strategies in Venous Thromboembolism: A Narrative Review of Pharmacological Innovations. Thrombosis Journal, 2026, 24, 74.	2.9	0
718	The Interplay of Heart Failure and Pulmonary Embolism: A Comprehensive Review. Heart Failure Clinics, 2026, 22, 301-311.	1.6	0
719	Systematic Review and Meta-Analysis on the Efficacy and Safety of Low Dose Anticoagulation Compared With Therapeutic Dose in the Extended Secondary Prophylaxis of Venous Thromboembolism. European Journal of Vascular and Endovascular Surgery, 2026, .	3.2	0
720	Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps. Cureus, 2026, 18, e111121.	1.3	0

#	Article	IF	Citations
721	Effectiveness and Safety of Direct Oral Anticoagulants in Patients With Thrombotic Antiphospholipid Syndrome and Venous Thrombosis: A Retrospective Cohort Study. Thrombosis Research, 2026, 264, 109759.	2.9	1
722	JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis. Circulation Journal, 2026, 90, CJ-25-1144.	4.0	9
723	Extended-Phase Anticoagulation for Pediatric Venous Thromboembolism After EINSTEIN Jr. Translational Pediatrics, 2026, 15, 205.	1.9	0
724	Full- Versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study. Seminars in Thrombosis and Hemostasis, 2026, .	4.1	0
725	Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Journal of the American College of Cardiology, 2026, 88, 1255-1283.	12.0	4
726	Bleeding Events During Anticoagulation After Acute Pulmonary Embolism: Real-Life Experience. Medicina (Lithuania), 2026, 62, 1278.	3.3	0
727	Embolia pulmonar: qué aporta la nueva guía AHA/ACC 2026. Revista Clinica Espanola, 2026, 226, 502610.	0.3	0
728	Venous Thrombotic and Thromboembolic Considerations in Stroke: An Expert Meeting Report on Future Directions for Clinical Trials. International Journal of Stroke, 2026, .	7.4	0
729	Low Molecular Weight Heparin vs. Rivaroxaban for Venous Thromboembolism Prevention After Surgery: Systematic Review and Meta-Analysis. Angiologia, 2026, .	0.1	0
730	Long-Term Antithrombotic Therapy in Patients With Short Bowel Syndrome: A European Society for Clinical Nutrition and Metabolism (ESPEN) Position Paper.. Clinical Nutrition, 2026, 64, 106741.	7.5	0
731	How to Safely Anticoagulate Patients With Renal Impairment. British Journal of Hospital Medicine (London, England: 2005), 2026, 87, 49737.	1.4	0
732	Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants. European Journal of Haematology, 2026, .	2.9	0
733	Pulmonary Embolism: What Does the New AHA/ACC 2026 Guide Add. Revista Clínica Española, 2026, 226, 502610.	1.1	0
734	1. The Japanese Journal of Phlebology, 2026, 37, 35-41.	0.3	0
735	Implikationen der API-CAT-Studie für die verlängerte Sekundärprophylaxe von krebsassoziierten venösen Thromboembolien. Phlébologie, 2026, 55, 196-206.	0.1	0
736	Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 2026, 32, 10760296261452847.	2.2	0
737	The First Month After Direct Oral Anticoagulants: A Window of Vulnerability. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106923.	3.3	0
738	Thrombophilia Work-Up and Clinical Outcomes in Indian Patients With Unprovoked Venous and Arterial Thrombosis Aged 18-50 Years. Bleeding, Thrombosis, and Vascular Biology, 2026, 5, 1-8.	0.3	0

#	Article	IF	Citations
739	Antiplatelet Therapy in Pulmonary Embolism: Mechanisms and Evidence. World Journal of Translational Medicine, 2026, .	0.0	0
740	Lipid-Lowering Therapy in Venous Thromboembolism: A Clinical Consensus Statement of the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Cardiovascular Pharmacotherapy, the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine (ESVM). European Journal of Preventive Cardiology, 2026, .	6.1	0
741	Rivaroxaban. , 2026, .		0
742	Managing Thrombotic Risk in Myeloproliferative Disorders. Expert Review of Hematology, 2026, .	2.7	0
743	Acute Pulmonary Embolism: Current Concepts in Risk Stratification and Management. Indian Journal of Medical Specialities, 2026, 17, 260-265.	0.4	0
744	Personalized Anticoagulant Therapy in Venous Thromboembolism: Current Role of Direct Oral Anticoagulants, Unmet Clinical Needs, and Future Perspectives on Factor XI Inhibition. Frontiers in Pharmacology, 2026, 17, 1959476.	5.3	0
745	Drug Selection for Long-Term Anticoagulant Therapy in Patients With Venous Thromboembolism. Flebologiya, 2026, 20, 258.	1.4	0
746	Venous Thromboembolic Disease. , 2027, .		0
747	Pulmonary Embolism and Deep Vein Thrombosis. , 2026, .		0
748	Contemporary Anticoagulation Management in Pulmonary Embolism. Thrombosis Research, 2026, 266, 109854.	2.9	0
749	Bleeding Risks With Direct Oral Anticoagulants Versus Aspirin: Comparison of Intention-to-Treat Versus On-Treatment Meta-Analyses. Thrombosis Research, 2026, .	2.9	0
750	Um novo olhar sobre a extensão da anticoagulação no tromboembolismo venoso. Jornal Vascular Brasileiro, 2026, .	1.0	0
751	Predictive Performance of Bleeding Risk Scores for Extended Anticoagulation in Pulmonary Embolism: Insights From the CURES-2 Registry. Thrombosis Research, 2026, 266, 109892.	2.9	0
752	De-escalated rivaroxaban in postoperative isolated distal deep vein thrombosis: a propensity score–matched study. Frontiers in Cardiovascular Medicine, 2026, 13, 1855986.	3.2	0
753	Integrated Management of Acute Pulmonary Embolism and the Post-Pulmonary Embolism Syndrome: Risk Stratification, Modern Therapies, and Long-Term Follow-Up. Frontiers in Cardiovascular Medicine, 2026, 13, 2002611.	3.2	0
754	Patient Selection and Evidence for Intervention in Deep Vein Thrombosis and Pulmonary Embolism. Journal of Clinical Medicine, 2026, 15, 8212.	3.8	0